EN

Publikationen

Brustzentrum

Seitenanfang Nach oben

Publkationen

Publikationen unserer Klinik

Publikationen der Klinik für Gynäkologie

    • Relevance of #Gal-#GalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients.
      Milde-Langosch K, Schütze D, Oliveira-Ferrer L, Wikman H, Müller V, Lebok P, Pantel K, Schröder C, Witzel I, Schumacher U.
      Breast Cancer Res Treatm 2015, DOI 10.1007/s10549-015-3425-0

    • 8p deletion is strongly linked to poor prognosis in breast cancer.
      Lebok P, Mittenzwei A, Kluth M, Özden C, Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wölber L, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E.
      Cancer biology & therapy 05/2015; DOI:10.1080/15384047.2015.1046025
    • Adjuvant therapy in lymph-node positive vulvar-cancer - the AGO-CaRE 1 study
      Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L.
      J Natl Cancer Inst 2015 Jan 24; 107(3)

    • Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
      Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C,Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.
      Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x.

    • Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
      Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero A Eur J Cancer 2015 Feb;51(3):352-8

    • Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study
      Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A
      Brit J Cancer 2015 Feb 17;112(4):660-6

    • Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
      Khan SS, Karn T, Symmans WF, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C.
      Breast Cancer Res Treat. 2015;149:789-97.

    • Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer.
      Gyorffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L.
      Int J Cancer. 2015;136:2091-8.

    • Utility of EFC quality indicators for colposcopy in daily practice: results from an independent, prospective multicenter trial.
      Luyten A, Hagemann I, Scherbring S, Boehmer G, Gieseking F, Woelber L, Glasenapp F, Hampl M, Kuehler-Obbarius C, van den Bergh M, Leeson S, Redman C, Petry KU; for "Studiengruppe Kolposkopie eV (SGK)" and "G-CONE (German Colposcopy Network)".
      Eur J Obstet Gynecol Reprod Biol. 2015 May 30;191:43-47.

    • A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
      Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.
      N Engl J Med. 2015 Feb 19;372(8):711-23

    • Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.
      Fasching PA, Brucker SY, Fehm TN, Overkamp F, Janni W, Wallwiener M, Hadji P, Belleville E, Haberle L, Taran FA, Luftner D, Lux MP, Ettl J, Müller V, Tesch H, Wallwiener D, Schneeweiss A.
      Geburtshilfe Frauenheilkd. 2015;75:41-50.

    • Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic acid induced 2.
      Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefstrom J, Wilmanns M,Müller V, Pantel K, Wikman H.
      Cancer Discovery 5(5):506-19. doi: 10.1158/2159-8290

    • Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapydagger.
      Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G.
      Ann Oncol. 2015;26:95-100

    • Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: no evidence of oncogenic or tumor-suppressive function.
      Von Bülow C, Oliveira-Ferrer L, Löning T, Trillsch F, Mahner S, Milde-Langosch K
      Mol Clin Oncol (2015), in press.

    • Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties.
      Oliveira-Ferrer L, Kürschner M, Labitzky V, Wicklein D, Müller V, Lüers G, Schumacher U, Milde-Langosch K, Schröder C
      J Cancer Res Clin Oncol (2015), DOI 10.1007/s00432-015-1925-2
    • Systemic treatment of vulvar cancer
      Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Mueller V, Jaenicke F, Woelber L
      Expert Rev Anticancer Ther. 2015 [accepted]

    • A systemic model specification procedure for an Illness-Death Model without recovery Eulenburg C, Mahner S, Woelber L, Wegscheider K
      PLOS ONE 2015 [accepted]

    • Sexual activity and function in patients with gynecological malignancies after completed treatment
      Grimm D, Hasenburg A, Eulenburg C, Steinsiek L, Mayer S, Eltrop S, Prieske K, Trillsch F, Mahner S, Woelber L
      Int J Gynecol Cancer 2015

    • Alopecia as a surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients
      Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Pujade-Lauraine E, Kristensen G, Herrstedt J, du Bois A, Pfisterer J
      Eur J Cancer 2015 Mar 11 [Epub ahead of print]

    • Olaparib combined with chemotherapy for recurrent platinum sensitive ovarian cancer: a randomized Phase II study
      Oza AM, Cibula D, Oaknin A, Poole C, Mathijssen R, Sonke GS, Colombo N, Spacek J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe E, Dougherty B, Barret JC, Friedlander M
      Lancet Oncol 2015 Jan;16(1):87-97

    • Surgical and systemic management of endometrial cancer: an international survey.
      Fotopoulou C, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, Casado A, Mahner S, Herzog TJ, Kehoe S, Vergote I, Miller DS, Marth C, Fujii S, Sehouli J
      Arch Gynecol Obstet 2015 Apr;291(4):897-905.

    • Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study
      Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O,Trillsch F, Mahner S, Strauss HG, Wimberger P, Reuss A, du Bois A
      Support Care Cancer 2015 Jan;23(1):117-23

    • Mikronährstoffe in der Therapie männlicher Infertilität
      Laakmann E, Bühling KJ.
      Gynakol Geburtsmed Gynakol Endokrinol 2015; 11(1): 4-19

    • L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
      Doberstein K, Milde-Langosch K, Bretz NP, Schirmer U, Harari A, Witzel I, Ben-Arie A, Hubalak M, Müller-Holzner E, Zeimet AG, Altevogt P, Fogel M and Reinold S.
      BMC Cancer 14:958 (2014)

    • Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.
      Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, Jänicke F..
      BMC Cancer. 2014 Nov 4;14(1):806

    • Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients..
      Wikman H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal M, Iljin K, Huhtala H, Terracciano L, Kallioniemi A, Sauter G, Müller V, Witzel I, Lamszus K, Kemming D, Pantel K.
      Oncotarget. 2014 May 30;5(10):3076-87

    • Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)dagger.
      von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B, groups GA-Bs. Ann Oncol. 2014;25:2363-72.

    • Increased serum levels of circulating exosomal microRNA-373 in basal-like and receptor-negative breast cancer patients.
      Eichelser C, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H.
      Oncotargets 5(20):9650-63 (2014)

    • Role of uPA and PAI-1 mRNA expression as prognostic factors in molecular subtypes of breast cancer.
      Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A,Laakmann E, Schütze D, Jänicke F, Müller V.
      OncoTargets and Therapy 7: 2205-2213 (2014)

    • Utility and Reproducibility of the International Federation for Cervical Pathology and Colposcopy Classification of Transformation Zones in Daily Practice: A Multicenter Study of the German Colposcopy Network.
      Luyten A, Buttmann-Schweiger N, Hagemann I, Scherbring S, Boehmer G,Gieseking F, Woelber L, Glasenapp F, Hampl M, Kuehler-Obbarius C, van den Bergh M, Petry KU; For the German Colposcopy Network (G-CONE) and the German Colposcopy Study Group.
      J Low Genit Tract Dis. 2014 Aug 1. [Epub ahead of print]

    • Cyclin D1 gene amplification is highly homogeneous in breast cancer.
      Burandt E, Grunert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkotter U, Simon R, Sauter G, Wilczak W.
      Breast Cancer. 2014.

    • Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri.
      Choschzick M, Woelber L, Gieseking F, Oosterwijk E, Tennstedt P.
      Histopathology. 2014 Mar;64(4):600-2. doi: 10.1111/his.12288.

    • Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients.
      Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Jänicke F, Müller V, Terracciano L, Simon R, Sauter G, Wilczak W, Lebok P.
      Oncol Rep. 2014.

    • Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
      Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L, PrefHer Study G.
      Ann Oncol. 2014;25:1979-87.

    • Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
      Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lubbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H.
      Breast Cancer Res Treat. 2014;147:61-8.

    • Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study.
      Müller V, Fuxius S, Steffens C-C, Lerchenmüller C, Luhn B, Vehling-Kaiser U, Hurst U, Hahn L-J, Soeling U, Wohlfarth T, Zaiss M.
      Oncology Research and Treatment. 2014;37:6-.

    • Systemische Therapie: HER2-positive Mammakarzinome.
      Müller V.
      In: Untch M, Harbeck N, Thomssen C, Costa S, editors. Colloquium Senologie. München: Agileum Verlag; 2014. p. 179-99.

    • Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT Study
      Trillsch F, Mahner S, Woelber L, Vettorazi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P. Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A
      Ann Oncol 2014 Jul;25(7):1320-7

    • Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
      Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.
      Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186.

    • Clinical Management of epithelial ovarian cancer during pregnancy
      Grimm D, Woelber L, Trillsch F, Keller-V Amsberg G, Mahner S
      Eur J Cancer. 2014 Mar;50(5):963-71

    • Surgery or topical therapy for vulval intraepithelial neoplasia (Editorial)
      Mahner S, Woelber L
      Lancet Oncol. 2014 Nov;15(12):1287-8

    • Quality of life as primary endpoint in ovarian cancer trials
      Mahner S, Burges A
      Lancet Oncol. 2014 Apr;15(4):363-4.

    • Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer
      Despierre E, Moisse M, Yesilyurt B, Sehouli J, Braicu I, Mahner S, Castillo-Tong DC, Zeillinger R, Lambrechts S, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I
      Gynecol Oncol 2014 Dec;135(3):415-22

    • HIFIalpha is an independent prognostic factor for overall survival in advanced primary ovarian cancer - a study of the OVCAD consortium
      Braicu EI, Luketina H, Richter R, Castillo-Tong D, Lambrechts S, Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J
      OncoTargets Ther 2014 Sep 11;7:1563-9

    • Overexpression of the epithelial adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J
      Gynecol Oncol 2014 Jul;25(3):221-8.

    • BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
      Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI
      Eur J Cancer. 2014 Aug;50(12):2090-8.

    • Ambivalent role of pFAK-Y397 in serous ovarian cancer - a study of the OVCAD consortium Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I,Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils D
      Mol Cancer. 2014 Mar 21;13:67

    • Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - A study of the OVCAD consortium
      Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R
      Eur J Cancer 2014 Jan;50(1):99-110

    • Consensus Review for Cervical Adenocarcinoma
      Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K Gynecologic Cancer InterGroup (GCIG)
      Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S96-S101

    • Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors)
      Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A Gynecologic Cancer InterGroup (GCIG)
      Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S5-8

    • Consensus Review for Small Cell Carcinoma of the Cervix
      Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Avall-Lundqvist E, Pautier P, Reed NS, Fujiwara K Gynecologic Cancer InterGroup (GCIG)
      Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S102-8

    • GCIG Consensus Review for Endometrial Stromal Sarcoma
      Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nahm EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann A, Seddon B
      Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S67-72

    • GCIG Consensus Review for Vulvovaginal Melanomas
      Leitao MM Jr, Cheng X, Hamilton AL, Siddiqui NA, Jurgenliemk-Schulz I,Mahner S, Lundqvist EA, Kim K, Freyer G
      Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S117-22

    • What is the value of lymphadenectomy in early ovarian cancer
      Mahner S, Pfisterer J, Mohan GRA, Quinn M
      Controversies in Gynecologic Oncology - Ledermann J, Creutzberg K, Quinn M (Edit) 1st Edition 2014

    • Wie halte ich einen guten Vortrag?
      Müller V.
      Geburtshilfe Frauenheilkd. 2014;74:208-9.

    • Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer.
      Karn T, Rody A, Müller V, Schmidt M, Becker S, Holtrich U, Pusztai L.
      Genomics Data. 2014;2:354-6.

    • Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases.
      Joosse SA, Müller V, Steinbach B, Pantel K, Schwarzenbach H.
      Br J Cancer. 2014;Advance Online Publication: 1 July 2014.

    • Subcutaneous Administration of Monoclonal Antibodies in Oncology.
      Jackisch C, Müller V, Maintz C, Hell S, Ataseven B.
      Geburtshilfe und Frauenheilkunde. 2014;74:343-9.

    • Gentests beim Mammakarzinom
      Witzel I.
      Gynakol Geburtsmed Gynakol Endokrinol 2014; 10(2): 176-187

    • Sources of meaning in cancer patients - influences on global meaning, anxiety and depression in a longitudinal study.
      Scheffold K, Mehnert A, Müller V, Koch U, Harter M, Vehling S.
      European journal of cancer care. 2014;23:472-80.

    • Prävention von Nozebo-Effekten in der endokrinen Therapie.
      Heisig SR, Shedden-Mora MC, von Blanckenburg P, Schuricht F, Witzel I, Rief W, Albert US, Nestoriuc Y.
      FRAUENARZT 2014 (55) 10: 1002-1007

    • AKT3 regulates ErbB2, ErbB3 and estrogen receptor # expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice.
      Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.
      Cell Signal. 2014 Jan 24. doi: 10.1016/j.cellsig.2014.01.018. [Epub ahead of print]

    • Prognostic relevance of glycosylation-associated genes in breast cancer.
      Milde-Langosch K, Karn T, Schmidt M, zu Eulenburg C, Oliveira-Ferrer L, Wirtz RM, Schumacher U, Witzel I, Schütze D, Müller V.
      Breast Cancer Res Treatm DOI 10.1007/s10549-014-2949-z (2014)

    • OPG and PgR show similar cohort-specific effects as prognostic factors in ER positive breast cancer.
      Sänger N, Ruckhäberle E, Bianchini G, Heinrich T, Milde-Langosch K, Müller V, Rody A, Solomayer EF, Fehm T, Holtrich U, Becker S, Karn K.
      Mol Oncol, in press (2014)

    • The effect of micronutrient supplements on male fertility.
      Bühling KJ, Laakmann E.
      Curr Opin Obstet Gynecol. 2014 Apr 22. [Epub ahead of print]

    • The use of complementary and alternative medicine by women transitioning through menopause in Germany: results of a survey of women aged 45-60 years.
      Bühling KJ, Daniels B, Studnitz v. FSG, Eulenburg C.
      Complement Ther Med. 2014 Feb;22:94-8

    • Worldwide use of intrauterine contraception: a review.
      Bühling KJ, Lotke P, Black K, Zite N.
      Contraception. 2014 Mar;89(3):162-173.

    • Clinical management of epithelial ovarian cancer during pregnancy.
      Grimm D, Woelber L, Trillsch F, Keller-V Amsberg G, Mahner S.
      Eur J Cancer. 2014 Jan 23. pii: S0959-8049(14)00002-1. doi: 10.1016/j.ejca.2013.12.020. [Epub ahead of print

    • c-FOS suppresses ovarian cancer progression by changing adhesion.
      Oliveira-Ferrer L, Rößler K, Haustein V, Schröder C, Wicklein D, Maltseva D, Khaustova N, Samatov T, Tonevitsky A, Mahner S, Jänicke F, Schumacher U,Milde-Langosch K.
      Brit J Cancer, 2014 Br J Cancer 2014; 110: 753-763

    • Understanding the barriers and myths that limit the use of intrauterine contraception, particularly in nulliparous women: a European/Canadian subgroup analysis of a global survey of healthcare providers
      Bühling KJ, Hauck B, Dermout S, Ardaens S, Marions L.
      Eur J Obstet Gynecol 2014 Dec:183;146-54

    • A first-in-human study of PDC31 (a prostaglandin F2# receptor inhibitor) in patients with primary dysmenorrhea.
      Böttcher B, Laterza RM, Wildt L, Seufert RJ, Bühling KJ, Singer CF, Hill W, Griffin P, Jilma B, Schulz M, Smith RP.
      Human Reprod 2014 Nov:29;2465-73

    • Contraceptive Counseling and Self Prescription of Contraceptives of German Gynecologists: Results of a Nationwide Survey
      Bühling KJ, Klovekorn L, Daniels B, Studnitz FSG, Eulenburg C, Mueck AO. European Journal of Contraception and Reproductive Health Care 2014 Dec; 19:448-56

    • The effect of micronutrient supplements on male fertility
      Bühling KJ, Laakmann E.
      Curr Opin Obstet Gynecol. 2014 Dec;19:448-56

    • The use of complementary and alternative medicine by women transitioning through menopause in Germany: results of a survey of women aged 45-60 years
      Bühling KJ, Daniels B, Studnitz v. FSG, Eulenburg C.
      Complement Ther Med. 2014 Feb;22:94-8

    • Worldwide use of intrauterine contraception: a review.
      Bühling KJ, Lotke P, Black K, Zite N.
      Contraception. 2014 Mar;89(3):162-173

    • Sexuelle Probleme während und nach der Schwangerschaft
      Bühling KJ.
      Gynäkologe 2014 · 47:86-88

    • Bedeutung von Mikronährstoffen bei Kinderwunsch, in Schwangerschaft und Stillzeit
      Bühling KJ.
      Hebamme 2014; 27(1): 12-22

    • Mikronährstoffe in der Therapie männlicher Infertilität.
      Detinkina E, Bühling KJ.
      Gynakol Geburtsmed Gynakol Endokrinol in print

    • Sexuelle Probleme während und nach der Schwangerschaft
      Bühling KJ.
      Gynäkologe 2014 · 47:86-88

    • Bedeutung von Mikronährstoffen bei Kinderwunsch, in Schwangerschaft und Stillzeit.
      Bühling KJ.
      Hebamme 2014; 27(1): 12-22

    • Systematic follow-up and therapy monitoring in gynecological malignancies - is it really useful? Mahner S
      Anticancer Res 2014; 34: 40

    • Do we really need screening in gynecology?
      Mahner S
      Anticancer Res 2014; 34: 41

    • Neoadjuvant or postoperative therapy for advanced ovarian cancer
      Mahner S, Harter P, Hilpert F, Pfisterer J, du Bois A, Chi D
      Oncol Res Treat 2014;37(suppl 5):116

    • Lokaler Resektionsrand und Rezidivrisiko beim Plattenepithelkarzinom der Vulva - Ergebnisse einer Subgruppenanalyse der multizentrischen AGO CaRE-1 Studie
      Woelber L, Kosse J, Heiss C, Neuser P, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jückstock J, Hilpert F, De Gregorio N, Iborra S, Sehouli J, Habermann A, Hillemanns P, Fürst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Mahner S
      Geburtshilfe Frauenheilkd 2014; 74

    • Unabhängige Analyse der AGO-OVAR 12, einer GCIG/ENGOT-Intergroup Phase III Studie mit Nintedanib in der Firstline Therapie beim Ovarialkarzinom
      Mahner S, Hilpert F, Meier W, Sailer O, Hanker L, Canzler U, Sehouli J, Baumann K, Burges A, Gropp M, Hasenburg A, Belau A, Fehm T, Kosse J, Schmalfeldt B, Marme F, Cibula D, Richter B, Herwig U, Liebrich C, Gerber B, Potenberg J, Krabisch P, Thill M, Harter P, Kimmig R, de Gregorio N, Pfisterer J, Merger M, du Bois A
      Geburtshilfe Frauenheilkd 2014; 74

    • Resection margin and locoregional control in vulvar cancer: A subset analysis of the AGO CARE-1 multicenter study
      Woelber L, Sehouli J, Habermann A, Hillemanns P, Neuser P, Fuerst S, Strauss HG, Baumann KH; Thiel FC, Mustea A, Meier W, Harter P, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm TN, Luyten A, Hellriegel M,Mahner S
      J Clin Oncol 32, 2014 (suppl; abstr 5608)

    • Impact of adjuvant therapy in lymph-node positive vulvar cancer - The AGO-CaRE 1 (Chemo and Radiotherapy) study
      Petersen C, Woelber L, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Mahner S
      Radiotherapy and Oncology, Volume 111 Supplement 1 (2014) OC 0363

    • Progression-free survival in patients in with advanced ovarian cancer defined by GCIG criteria vs. RECIST criteria: Analysis of the secondary endpoint of the AGO-Ovar16 trial
      Mahner S, Jackisch C, Sehouli J, Rau J, Schmalfeldt B, Belau A, Richter B, Emons G, Park-Simon TW, Lueck HJ, Burges A, Fehm T, Feisel-Schwickardi G, Clemens M, du Bois A
      Oncol Res Treat 2014;37(suppl 1): 68

    • AGO Vulva CaRE-1 multicenter study - adjuvant radio(chemo)therapy in vulvar cancer
      Hillemanns P, Wölber L, Jückstock J, Neuser P, Hilpert F, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Fürst ST, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Petersen C, Mahner S
      Oncol Res Treat 2014;37(suppl 1): 70

    • Outcome parameters in node-negative vulvar cancer - a subset analysis of the AGO CaRE-1 study Wölber L, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Iborra S, Sehouli J, Habermann A, Hillemanns P, Fürst S, Strauss HG, Baumann KH, Thiel F, Mustea A, Meier W, du Bois A, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Griebel LF,Mahner S
      Oncol Res Treat 2014;37(suppl 1): 72

    • Role of radical tumor resection and hyperthermic perfusion in ovarian cancer
      Schmalfeldt B, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, Sehouli J, Harter P
      Oncol Res Treat 2014;37(suppl 5):116

    • Clinical significance of hemostatic activation markers in women with suspected ovarian cancer Claussen C, Rausch AV, Spath B, Lezius S, Bokemeyer C,Mahner S, Langer F
      Oncol Res Treat 2014;37(suppl 5):214

    • Estrogen-inactivating sulfotransferase has benefical effects in advanced serous ovarian cancer Mungenast F, Aust S, Ocko K, Klameth L, Cacsire Castilo- Tong D, Zeillinger R, Van Gorp T, Vergote I, Sehouli J, Mahner S, Fogel M, Thalhammer T
      Oncol Res Treat 2014;37(suppl 5):266

    • Early discontinuation of chemotherapy among elderly patients with ovarian cancer under clinical trial conditions - an analysis of the AGO study group
      Saß S, Hedderich J, Hempel AM, Harter P, Mahner S, Pfisterer J, du Bois A, Hilpert F
      Geburtshilfe Frauenheilkd 2014; 74

    • Prognostische Bedeutung von Zeitintervall und Staging-Prozeduren für Patientinnen mit primären Borderline-Tumoren des Ovars (BOT): Eine Subgruppen-Analyse der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ROBOT-Studie
      Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, De Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauß HG, Hellriegel M, Wimberger P, du Bois A
      Geburtshilfe Frauenheilkd 2014; 74

    • Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)
      Hilpert F, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner M, Hanker L, Thiel F, Emons G
      Geburtshilfe Frauenheilkd 2014; 74

    • AGO-OVAR 12: Eine randomisierte, Placebo-kontrollierte Phase III-Studie zum Einsatz von Carboplatin und Paclitaxel ± Nintedanib beim fortgeschrittenen Ovarialkarzinom (GCIG/ENGOT-Intergroup-Studie)
      Canzler U, Hilpert F, Meier W, Reuß A, Hanker LC, Sehouli J, Baumann K, Burges A, Gropp-Meier M, Hasenburg A, Belau A, Fehm T, Kosse J, Mahner S, Schmalfeldt B, Marmé F, Richter B, Cibula D, Harter P, Kimmig R, de Gregorio N, Pfisterer J, Merger M, du Bois A
      Geburtshilfe Frauenheilkd 2014; 74

    • Sexual activity and function in patients with preinvasive and invasive vulvar lesions after completed treatment
      Grimm D, Brummer O, zu Eulenburg C, Gieseking F, Schliedermann AK,Trillsch F, Mahner S, Woelber L
      Geburtshilfe Frauenheilkd 2014; 74

    • Die AGO-OVAR 2.20/PENELOPE Studie - Therapie des platinresistenten Ovarialkarzinoms mit Pertuzumab (P) und Chemotherapie (CT) nach Biomarker-unterstützter Präselektion von Patienten Kurzeder C, Schmalfeldt B, Grischke EM, Rau J, Meier W, Lück HJ, Hasenburg A, Belau A, Mahner S, Marmé F, Hilpert F, Gropp-Meier M, Zorr A, Vergote I, Hils R, Canzler U, Rein D, de Gregorio N, Jackisch C, Gerber B, du Bois A
      Geburtshilfe Frauenheilkd 2014; 74

    • Role of IGF1 in primary ovarian cancer - a study of the OVCAD European Consortium
      Rohr I, Zeilinger R, Heinrich M, Richter R, Concin N, Vergote I, Mahner S, Van Gorp T, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI
      Geburtshilfe Frauenheilkd 2014; 74

    • Lebensqualität und Sexualität bei Patientinnen mit einem Borderlinetumor des Ovars (eine Substudie der ROBOT-Studie der AGO-Ovar)
      Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O,Trillsch F, Mahner S, Strauss HG, Wimberger P, Reuss A, du Bois A
      Geburtshilfe Frauenheilkd 2014; 74

    • ENGOT-OV16/NOVA: a phase 3 randomized double-blind trial of maintenance with parp-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer
      Mirza MR, Monk BJ, Ledermann JA, Oza AM, Del Campo JM, Berek JS,Mahner S, Wenham RW, Vergote IB, Fabbro M, Marth C, Dørum A, Lorusso D, Katsaros D, Bruchim I, Malander S, Herrstedt J, Agarwal S, Martell RE, Matulonis U
      Ann Oncol (2014) 25 (suppl 4): iv325

    • surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT): A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.
      Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, De Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker LC, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Du Bois A
      J Clin Oncol 32, 2014 (suppl; abstr 5562)

    • Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
      Gonzalez-Martin A, Pautier P, Mahner S, Rau J, Colombo N, Ottevanger P, Del Campo JM, Berton-Rigaud D, Du Bois A, Freudensprung U, Walker RA, Kurzeder C
      J Clin Oncol 32, 2014 (suppl; abstr 5552)

    • Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).
      Emons G, Kurzeder C, Schmalfeldt B, Reuss A, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schroeder W, Lueck HJ, Heubner ML, Hanker LC, Thiel F, Hilpert F
      J Clin Oncol 32, 2014 (suppl; abstr 5565)

    • A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial)
      Matulonis U, Mahner S, Wenham RM, Ledermann JA, Monk BJ; Del Campo JM; Berek JS, Vergote I, Fabbro M, Katsaros D, Marth C, Lorusso D, Herrstedt J; Agarwal S; Martell RE Mirza MR
      J Clin Oncol 32, 2014 (suppl; abstr TPS5625)

    • A Influence of the postoperative residual tumor on the outcome of therapy with pazopanib in ovarian cancer (OC): A subgroup analysis of an international intergroup trial (AGO-OVAR16)
      Gropp-Meier M, Schmalfeld B, Belau A, Rau J, Richter B, Emons G, Hillemanns P, Lück HJ, Burges A, Fehm T, Harter P, Wimberger P, Baumann K, Kurzeder C, Canzler U, Meier W, Hanker LC, Mahner S, Kosse J, Sehouli J, Sütterlin M, Zorr A, du Bois
      Oncol Res Treat 2014;37(suppl 1): 69

    • Role of IGF1 in primary ovarian cancer - a study of the OVCAD European Consortium
      Rohr I, Braicu EI, Zeilinger R, Concin N, Richter R, Heinrich M, Mahner S, Van Gorp T, Trillsch F, Cacsire Castillo-Tong D, Chekerov R, Sehouli
      J Oncol Res Treat 2014;37(suppl 1): 69

    • Prognostic impact of the time interval between primary and re-staging surgery in patients with borderline ovarian tumours (BOT): An analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group
      Trillsch F, Mahner S, Rützel JD, Vettorazzi E, Reuss A, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Klaus B, Keyver-Paik KD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Fehm T, Meier W, Ewald-Riegler N, de Gregorio N, Hilpert F, du Bois A
      Oncol Res Treat 2014;37(suppl 1): 70

    • Sexual activity and function in patients with gynecological malignancies after completed treatment Grimm D, Hasenburg A, Steinsiek L, Trillsch F, Mayer S, Eltrop S, Mahner S, Woelber L
      Oncol Res Treat 2014;37(suppl 1): 71

    • AGO-OVAR 12: A Randomized Placebo-controlled GCIG/ ENGOT-Intergroup Phase III trial of standard frontline chemotherapy +/- Nintedanib for advanced ovarian cancer
      Harter P, Kimmig R, de Gregorio N, Reuss A, Pfisterer J, Cibula D, Hilpert F, Meier W, Hanker LC, Canzler U, Sehouli J, Baumann K, Burges A, Gropp-Meier M, Hasenburg A, Belau A, Fehm T, Kosse J, Mahner S, Schmalfeldt B, Marme F, Richter B, Herwig U, Liebrich C, Gerber B, Potenberg J, Krabisch P, Thill M, Merger M, du Bois A
      Oncol Res Treat 2014;37(suppl 1): 74

    • Results of an international Intregroup randomized phase III trial of pazopanib versus placebo (AGO-OVAR16). Subgroup Analysis of toxicity and clinical outcome in the Asian and Non-Asian population
      Sehouli J, Harter P, Wimberger P, Rau J, Baumann K, Kurzeder C, Canzler U, Meier W, Hanker LC, Mahner S, Krabisch P, Reiter WW, Aminossadati B, du Bois A
      Oncol Res Treat 2014;37(suppl 1): 75

    • Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) expression correlates with negative estrogen and progesteron receptor status and high grading in breast cancer.
      Schröder C, Milde-Langosch K, Gebauer F, Schmidt K, Müller V, Wirtz RM, Meyer-Schwesinger C, Schlüter H, Sauter G, Schumacher U.
      J Cancer Res Clin Oncol 139(10):1745-55 (2013)

    • Surgical intervention in relapsed ovarian cancer is beneficial: pro.
      Harter P, Heitz F, Mahner S, Hilpert F, du Bois A.
      Ann Oncol. 2013 Dec;24 Suppl 10:x33-34. doi: 10.1093/annonc/mdt466

    • The prognostic significance of Jun transcription factors in ovarian cancer.
      Eckhoff K, Flurschütz R, Trillsch F, Mahner S, Milde-Langosch K.
      J Cancer Res Clin Oncol 139(10):1673-80 (2013)

    • Platelet-Derived Growth Factor Receptor Beta Serum Concentrations during First-Line Therapy in Ovarian Cancer. Mathey S, Graeser MK, Zu Eulenburg C,Woelber L, Trillsch F, Jänicke F, Müller V, Milde-Langosch K, Mahner S.
      Oncology 85(2):69-77 (2013)

    • Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
      Schütze D, Milde-Langosch K, Witzel I, Rody A, Karn T, Schmidt M, Choschzick M, Jänicke F, Müller V.
      J Cancer Res Clin Oncol. 2013, 139(5):747-54
    • Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells.
      Dippel V, Milde-Langosch K, Wicklein D, Schumacher U, Altevogt P, Oliveira-Ferrer L, Jänicke F, Schröder C.
      J Cancer Res Clin Oncol. 2013 ; 139(1):107-21

    • Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.
      Oliveira-Ferrer L, Wellbrock J, Bartsch U, Murga Penas EM, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G.
      Mol Cancer. 2013 Nov 20;12(1):144.

    • Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
      Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schütze D, Rausch A, Jänicke F, Milde-Langosch K, Müller V.
      J Cancer Res Clin Oncol. 2013; 139(5):809-16

    • Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.
      Burandt E, Jens G, Holst F, Jänicke F, Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R, Sauter G, Lebeau A.
      Breast Cancer Res Treat. 2013; 137(3):745-53.

    • Management of patients with vulvar cancer: a perspective review according to tumour stage.
      Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jänicke F, Mahner S
      Ther Adv Med Oncol. 2013; 5(3):183-92.

    • Secondary Sentinel Node Biopsy After Previous Excision of the Primary Tumor in Squamous Cell Carcinoma of the Vulva.
      Woelber L, Grimm D, Vettorazzi E, Wisotzki C, Trillsch F, Jänicke F, Schwarz J, Choschzick M, Mahner S.
      Ann Surg Oncol. 2013; 20(5):1701-6.
    • Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
      Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jänicke F, Untch M, Thomssen C, Harbeck N.
      Breast Cancer Res Treat. 2013; 138(3):839-50.

    • Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
      Dohrmann T, Kutup A, Mahner S, Müller V, Jänicke F, Izbicki JR, Vashist YK.
      J Clin Oncol. 2013 20;31(12): 208-10.

    • Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
      Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C.
      Eur J Cancer. 2013; 49(8):1825-35.

    • Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
      Schütze D, Milde-Langosch K, Witzel I, Rody A, Karn T, Schmidt M,

    • Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
      Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM.
      Breast Cancer Res Treat. 2013 Jan;137(1):57-67.

    • The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
      Eiermann W; Rezai M; Kummel S; Kuhn T; Warm M; Friedrichs K; Schneeweiss A; Markmann S; Eggemann H; Hilfrich J; Jackisch C; Witzel I; Eidtmann H; Bachinger A; Hell S; Blohmer J
      Ann Oncol. 2013 Mar;24(3):618-24.

    • Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era.
      Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting (Mahner S etc.).
      Int J Gynecol Cancer. 2013 Oct;23(8):1528-34.

    • Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - A study of the OVCAD consortium.
      Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
      Eur J Cancer. 2014 Jan;50(1):99-110.

    • The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA, Bujard H, Olek A, Olek K, Gellhaus K, Braicu I, Könsgen D, Fryer C, Ravot E, Hellwag A, Westerfeld N, Gruss OJ, Meissner M, Hasan MT, Weber M, Hoffmüller U, Zimmermann S, Loddenkemper C, Mahner S, Babel N, Berns E, Adams R, Zeilinger R, Baron U, Vergote I, Maughan T, Marme F, Dickhaus T, Sehouli J, Olek S.
      Epigenetics. 2013 Nov 1;8(11):1226-35.

    • Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
      Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
      BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422

    • The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
      Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T,Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.
      Gynecol Oncol. 2013 Oct;131(1):15-20.

    • Adjuvant therapy in node-positive vulvar cancer.
      Mahner S, Trillsch F, Kock L, Rohsbach D, Petersen C, Kruell A, Harter P,Jaenicke F, Woelber L.
      Expert Rev Anticancer Ther. 2013 Jul;13(7):839-44

    • Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).
      Trillsch F, Ruetzel JD, Herwig U, Doerste U, Woelber L, Grimm D, Choschzick M, Jaenicke F, Mahner S.
      J Ovarian Res. 2013 Jul 9;6(1):48. doi: 10.1186/1757-2215-6-48.

    • Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.
      Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J.
      J Ovarian Res. 2013 Jun 28;6(1):42. doi: 10.1186/1757-2215-6-42

    • Management of patients with vulvar cancer: a perspective review according to tumour stage.
      Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S.
      Ther Adv Med Oncol. 2013 May;5(3):183-92.

    • A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
      Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.
      BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.

    • Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
      Dohrmann T, Kutup A, Mahner S, Müller V, Jaenicke F, Izbicki JR, Vashist YK.
      J Clin Oncol. 2013 Apr 20;31(12):e208-10. doi: 10.1200/JCO.2012.45.1708. Epub 2013 Mar 18.

    • Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
      du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S; Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
      Eur J Cancer. 2013 May;49(8):1905-14. doi: 10.1016/j.ejca.2013.01.035

    • Towards individualised treatment in ovarian cancer.
      Mahner S, Pfisterer J.
      Lancet Oncol. 2013 Feb;14(2):101-2.

    • Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
      Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
      Int J Gynecol Cancer. 2013 Feb;23(2):268-75.

    • Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
      Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.
      Gynecol Oncol. 2013 Feb;128(2):245-51.

    • Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium.
      Melmer A, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet AG, Castillo-Tong DC, Ebenbichler CF, Zeillinger R, Dieplinger H.
      Gynecol Oncol. 2013 Jan;128(1):38-43.

    • Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
      Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.
      Ann Surg Oncol. 2013 Apr;20(4):1348-54.

    • Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.
      Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R.
      Gynecol Oncol. 2013 Jan;128(1):15-21.

    • Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.
      Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A.
      Eur J Cancer. 2013 Jan;49(1):142-9

    • AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013.
      Harbeck N, Scharl A, Thomssen C, Müller V.
      Breast Care (Basel). 2013 Jun;8(3):181-5. doi: 10.1159/000353590.

    • AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013.
      Scharl A, Thomssen C, Harbeck N, Müller V.
      Breast Care (Basel). 2013 Jun;8(3):174-80. doi: 10.1159/000353617.

    • Sources of meaning in cancer patients - influences on global meaning, anxiety and depression in a longitudinal study.
      Scheffold K, Mehnert A, Müller V, Koch U, Härter M, Vehling S.
      Eur J Cancer Care (Engl). 2013 Nov 25. doi: 10.1111/ecc.12152

    • Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
      Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L.
      Breast Cancer Res. 2013 Sep 23;15(5):R86.

    • Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.
      Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA.
      PLoS One. 2013 Sep 18;8(9):e75038. doi: 10.1371/journal.pone.0075038. eCollection 2013

    • German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
      von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S.
      J Clin Oncol. 2013 Oct 1;31(28):3531-9. doi: 10.1200/JCO.2012.47.2167.

    • Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
      Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group.
      Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8.

    • Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.
      von Minckwitz G, Schmitt WD, Loibl S, Müller BM, Blohmer JU, Sinn BV, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching PA, Karn T, Müller V, Jackisch C, Denkert C.
      Clin Cancer Res. 2013 Aug 15;19(16):4521-31.

    • Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
      Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, Witzel I, Westphal M, Brandt B, Müller V, Pantel K, Wikman H.
      Am J Pathol. 2013 Jul;183(1):83-95.

    • Circulating tumor cells in breast cancer.
      Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, Hartkopf A, Fehm T.
      Clin Chim Acta. 2013 Aug 23;423:39-45.

    • Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
      Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S.
      J Clin Oncol. 2013 Jul 10;31(20):2532-9.

    • CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
      Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
      Lancet Oncol. 2013 Mar;14(3):244-8.

    • The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
      Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN.
      Breast Cancer Res Treat. 2013 Jan;137(2):503-10.

    • Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
      Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart M, Pierga JY.
      Cancer Metastasis Rev. 2013 Jun;32(1-2):179-88.

    • Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri.
      Choschzick M, Woelber L, Gieseking F, Oosterwijk E, Tennstedt P.
      Histopathology. 2014 Mar;64(4):600-2. doi: 10.1111/his.12288. Epub 2013 Nov 12.

    • Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
      Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K; HERACLES/SCALE Study Group.
      Int J Cancer. 2013 Feb 15;132(4):854-67.

    • 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).
      Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Dimpfl T, Eiermann W, Fehm T, Friese K, Jänicke F, Janni W, Jonat W, Kiechle M, Köhler U, Lück HJ, Maass N, Possinger K, Rody A, Scharl A, Schneeweiss A, Thomssen C, Wallwiener D, Welt A.
      Breast Care (Basel). 2013 Jun;8(3):221-9.

    • Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.
      Burandt E, Schreiber M, Stein A, Minner S, Clauditz TS, Bokemeyer C, Jänicke F, Fisch M, Izbicki JR, Knecht R, Sauter G, Stahl PR.
      Genes Chromosomes Cancer. 2014 Mar;53(3):228-39.

    • Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
      Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.
      Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813.

    • Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
      Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C; Chemo-N 0 Study Group.
      Eur J Cancer. 2013 May;49(8):1825-35. doi: 10.1016/j.ejca.2013.01.007.

    • Therapy of recurrent ovarian cancer - Systemic and operative options [German]
      Mahner S, Woelber L, Harter P, Hilpert F, Wagner U, Jaenicke F, Trillsch F.
      Gynäkologe 2013 Aug;46(8):560-564.

    • Anti-mullerian hormone: usefulness in clinical practice.
      Bühling KJ, Stute P, Ziller V.
      Int J Endocrinol. 2013;2013:791386. doi: 10.1155/2013/791386.

    • Worldwide use of intrauterine contraception: a review.
      Bühling KJ, Zite NB, Lotke P, Black K; for the INTRA Writing Group.
      Contraception. 2013 Nov 25. pii: S0010-7824(13)00733-6. doi: 10.1016/j.contraception.2013.11.011.

    • The value of complementary and alternative medicine in the treatment of climacteric symptoms: results of a survey among German gynecologists.
      von Studnitz FS, Eulenburg C, Mueck AO, Bühling KJ.
      Complement Ther Med. 2013 Oct;21(5):492-5. doi: 10.1016/j.ctim.2013.07.005.

    • The effect of micronutrient supplements on female fertility.
      Bühling KJ, Grajecki D.
      Curr Opin Obstet Gynecol. 2013 Jun;25(3):173-80. doi: 10.1097/GCO.0b013e3283609138.

    • Attitude of German women towards hormone therapy: results of a lay survey.
      Bühling KJ, Daniels B, Studnitz FS, Eulenburg C, Mueck AO.
      Gynecol Endocrinol. 2013 May;29(5):460-4. doi: 10.3109/09513590.2012.754881

    • Tumorzellen im Blut als Prognosefaktor beim Mammakarzinom
      Müller V.
      Onkologe 2013 DOI 10.1007/s00761-012-2401-0

    • Renaissance der Hormonersatztherapie in Deutschland
      Bühling KJ
      Menopause & Contraception 2013;1: 1-16

    • Erfolgschancen assistierter reproduktionsmedizinischer Therapien (ART)
      Bühling KJ
      Gynakol Geburtsmed Gynakol Endokrinol 2013; 9(3): 208-219

    • Hormonimplantate zur Kontrazeption bei der Frau
      Rabe T, Ahrendt HJ, Merkle E, Peters K, Albring C, Bitzer J, Bühling KJ, Egarter C, König K, Ludwig M, Merki G, Mueck AO
      J. Reproduktionsmed. Endokrinol 2013; 10 (3), 168-180

    • Intrauterine hormonelle Kontrazeption
      Römer T, Bühling K.J.
      Gynäkologische Endokrinologie 2013; 11:188-196

    • Erhöhte kardiovaskuläre Mortalität in der (späteren) Postmenopause
      Mueck AO, Bühling KJ.
      Gynäkologische Endokrinologie 2013; 11:256-263

    • Einsatz intrauteriner Kontrazeptiva in Deutschland Ergebnisse einer Umfrage unter 150 Gynäkologen
      Bühling KJ.
      Frauenarzt 2013; 54:248-250

    • Sichtweise von Frauenärzten sowie Patientinnen zur HRT Ergebnisse zweier bundesweiter Umfragen.
      Bühling KJ.
      Frauenarzt 2013; 54: 472-475

    • Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium.
      Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, Zeillinger R, Pils D.
      Mol Cancer. 2012 Sep 14;11:69. doi: 10.1186/1476-4598-11-69.

    • Fetal development of complex autonomic control evaluated from multiscale heart rate patterns.
      Hoyer D, Nowack S, Bauer S, Tetschke F, Rudolph A, Wallwitz U, Jänicke F,Heinicke E, Goetz T, Huonker R, Witte OW, Schleußner E, Schneider U.
      Am J Physiol Regul Integr Comp Physiol. 2012 Dec 26. [Epub ahead of print]

    • Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
      Grob TJ, Heilenkötter U, Geist S, Paluchowski P, Wilke C, Jänicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, Lebeau A.
      Breast Cancer Res Treat. 2012; 134(2):561-7.

    • Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.
      Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Müller V,Mahner S, Jänicke F, Wölber L, Milde-Langosch K.
      BMC Cancer. 2012; 12:140

    • High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.Minner S, Luebke AM, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W.
      Histopathology. 2012; 61(3):445-53

    • The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
      Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups
      Breast Cancer Res Treat. 2012; 131(1):295-306.

    • Association with Loss of PRKCDBP Expression in Brain Metastases.
      Wikman H, Sielaff-Frimpong B, Kropidlowski J, Witzel I, Milde-Langosch K, Sauter G, Westphal M, Lamszus K, Pantel K
      PLoS One;7(10):e47537.
      doi: 10.1371/journal.pone.0047537. Epub 2012 Oct 31

    • Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial.
      Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V
      Br J Cancer; 107(6):956-60

    • Prognostic impact of circulating tumor cells assessed with the CellSearch AssayTM and AdnaTest BreastTM in metastatic breast cancer patients: the DETECT study
      Müller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Study group T
      Breast Cancer Research 2012, 14:R118

    • Lost in effusion
      Trillsch F, Aberle J, Regier M, Choschzick M, Mahner S (2012)
      The Lancet : Volume 380, Number 9841, 11 August 2012

    • Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP).
      Duesing N, Schwarz J, Choschzick M, Jänicke F, Gieseking F, Issa R, Mahner S, Wölber L.(2012)
      Arch Gynecol Obstet. 2012; 289 (6):1549-54
    • Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells
      Joosse SA, Hannemann J, Spötter J, Bauche A, Andreas A, Müller V, Pantel K (2012)
      Clin Cancer Res online Jan 6.
    • Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation
      Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M & Altevogt P (2012);Ann Oncol. 2012 Jul;23(7):1795-802
    • Role of cyclin D1 amplification and expression in vulvar carcinomas
      Choschzick M, Hess S, Tennstedt P, Holst F, Bohlken H, Gieseking F, Mahner S, Wölber L, Simon R & Sauter G (2012)
      Hum Pathol, in press
    • BIRC2 amplification in squamous cell carcinomas of the uterine cervix
      Choschzick M, Tabibzada AM, Gieseking F, Wölber L, Jänicke F, Sauter G & Simon R (2012)
      Virchows Arch, in press
    • Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
      Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L & Mahner S(2012)
      Ann Oncol 23, 1185-9
    • Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
      Grob TJ, Heilenkotter U, Geist S, Paluchowski P, Wilke C, Jänicke F, Quaas A, Wilczak W, Choschzick M, Sauter G & Lebeau A (2012)
      Breast Cancer Res Treat, in press
    • Fetal development assessed by heart rate patterns--time scales of complex autonomic control
      Hoyer D, Nowack S, Bauer S, Tetschke F, Ludwig S, Moraru L, Rudoph A, Wallwit U, Jänicke F, Haueisen J, Schleussner E & Schneider U (2012)
      Comput Biol Med 42, 335-41
    • Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients
      Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Müller V, Mahner S, Jänicke F, Wölber L & Milde-Langosch K (2012)
      BMC Cancer 12, 140
    • Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion
      Jackisch C, Luck HJ, Untch M, Bischoff J, Müller V, Schmidt M, Thill M & Kiechle M (2012)
      Breast Care (Basel) 7, 137-143
    • A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
      Mahner S, Oskay-Ozcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P, Belau A, Ruhmland B, Heuser T, Kolbl H, Markmann S & Sehouli J (2012)
      J Cancer Res Clin Oncol, in press
    • Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer
      Marme F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, Sehouli J, Braicu I, Vergote I, Isabella C, Mahner S, Ferschke I, Rom J, Sohn C, Schneeweiss A & Altevogt P (2012)
      Int J Cancer 131, E586-91
    • Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium
      Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P & Zeillinger R (2012)
      Cancer Sci, in press
    • Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data
      Polterauer S, Vergote I, Conci N, Braicu I, Chekerov R, Mahner S, Wölber L, Cadron I, Van Gorp T, Zeillinger R, Castillo-Tong DC & Sehouli J (2012)
      Int J Gynecol Cancer 22, 380-5
    • Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients
      Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V & Pantel K (2012)
      Breast Cancer Res Treat, in press
    • Relevance of PTEN loss in brain metastasis formation in breast cancer patients
      Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Müller V, Westphal M & Pantel K (2012)
      Breast Cancer Res 14, R49
    • Detection of Activated Leukocyte Cell Adhesion Molecule in the Serum of Breast Cancer Patients and Implications for Prognosis
      Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Ihnen M, Jänicke F & Milde-Langosch K (2012)
      Oncology 82, 305-312
    • Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment
      Wölber L, Eulenburg C, Choschzick M, Kruell A, Petersen C, Gieseking F, Jänicke F & Mahner S (2012)
      Int J Gynecol Cancer 22, 503-8
    • EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome
      Wölber L, Hess S, Bohlken H, Tennstedt P, Eulenburg C, Simon R, Gieseking F, Jänicke F, Mahner S & Choschzick M (2012)
      J Clin Pathol 65, 133-9
    • The Relationship between sonographically-estimated fetal subcutaneous adipose tissue measurements and neonatal skinfold measurements in neonates of women with normal glucose tolerance and gestational diabetes.
      Bühling KJ, Doll I, Siebert G, Catalano PM. (2012)
      Ultrasound Obstet Gynecol. 2012 May;39(5):558-62
    • Attitude of German gynaecologists among prescribing hormone replacement therapy before and eight years after the Women´s Health Initiative Trial (WHI).
      Bühling KJ, Studnitz v. FSG, Jantke A, Eulenburg z. C, Mueck AO. (2012)
      Climacteric 2012 Aug;15(4):326-31.
    • Self-prescription of hormone replacement therapy in female gynaecologist 8 years after WHI study in Germany.
      Bühling KJ, Studnitz FSG v., Jantke A., Eulenburg C., Mueck AO. (2012)
      Menopause, in print
    • Effect of Cimicifuga racemosa and Agnus castus on climacteric symptoms - a systematic review.
      Laakmann E, Grajecki D, Zyriax BC, Bühling KJ. (2012)
      Gynecol Endocrinol, in print
    • Barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women.
      Black K, Lotke P, Bühling KJ, Zite N. (2012)
      Eur J Contracep Reprod, published online
    • The effect of micronutrient supplements on female fertility: a systematic review.
      Grajecki D, Zyriax BC, Bühling KJ.(2012)
      Arch Gynecol Obstet. 2012 May;285(5):1463-71.
    • Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries
      Bühling KJ, Eydeler U, Borregaard S, Schlegelmilch R, Suesskind M. (2012)
      Arzneimittelforschung/DrugReport published online
    • Geburtserleben der männlichen Partner und Erwartungen hinsichtlich ihrer Sexualität nach Miterleben der Geburt ihres Kindes. Ergebnisse einer Pilotstudie.
      Awad O, Bühling KJ.(2012)
      Gyn Praktische Gynäkologie. In print
    • Schilddrüse und Schwangerschaft. Seminar in Gynäkologischer Endokrinologie.
      Bühling KJ. (2012)
      in print.
    • Non-hormonal intrauterine Contraception.
      Ahrendt HJ, Bühling KJ.(2012)
      Seminar in Gynäkologischer Endokrinologie, in print.
    • Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood - a meta-analysis.
      Doege K, Grajecki D, Zyriax BC, Detinkina E, Eulenburg C, Bühling KJ. (2012)
      Br J Nutr 107:1-6
    • Diagnostics and therapy of Polycystic Ovarian Syndrome - Results of a survey among German gynecologists with a review on literature
      Doll I, Doll R, Bühling KJ. (2012)
      Arch Gynecol Obstet 285: 689-697
    • Buchkapitel zu: gynäkologischen Tumoren und MammaCA (Müller, Mahner, Wölber) in:
      Thorsten Frenzel, Friedemann Honecker, Andreas Krüll, Cordula Petersen, Emre F. Yekebas
      Tumorerfassung mit Erfassungsbögen und Leitlinien für die interdisziplinäre Diagnostik und Therapie.
      2012, 328 S., 51 ISBN: 9783131539618

    • Adhesion of small cell lung cancer cells to E- and P-Selectin under physiological flow conditions: implications for metastasis formation.
      Richter U, Schröder C, Wicklein D, Lange T, Geleff S, Dippel V, Schumacher U, Klutmann S (2011)
      Histochem Cell Biol. 135: 499-512

    • Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
      Karn T., Pusztai L., Ruckhaberle E., Liedtke C., Müller V., Schmidt M., Metzler D., Wang J., Coombes K.R., Gatje R., Hanker L., Solbach C., Ahr A., Holtrich U., Rody A., Kaufmann M. (2011)
      Eur J Cancer 48(1):12-23.
    • Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
      Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A.
      PLoS One. 2011;6(12):e28403.
    • A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors.
      Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Böhm D, Gebhard S, Petry IB, Lebrecht A, Cadenas C, Marchan R, Stewart J, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.
      Clin Cancer Res; 2011, 18(9); 2695-703.

    • Detect Study Group T.: Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
      Müller V., Riethdorf S., Rack B., Janni W., Fasching P., Solomayer E., Aktas B., Kasimier-Bauer S., Zeitz J., Pantel K., Fehm T. (2011)
      Breast Cancer Res, Vol. 13: R71

    • Health-related quality of life and patient-defined benefit of clobetasol 0 05% in women with chronic lichen sclerosus of the vulva
      Schwegler J , Schwarz J , Eulenburg C , Blome C , Ihnen M , Mahner S , Jänicke F , Augustin M & Wölber L (2011)
      Dermatology 223, 152-60

    • Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel
      Kantelhardt E J , Vetter M , Schmidt M , Veyret C , Augustin D , Hanf V , Meisner C , Paepke D , Schmitt M , Sweep F , von Minckwitz G , Martin P M , Jänicke F , Thomssen C & Harbeck N (2011)
      BMC Cancer 11, 140

    • Delta133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
      Hofstetter G , Berger A , Schuster E , Wolf A , Hager G , Vergote I , Cadron I , Sehouli J , Braicu E I , Mahner S , Speiser P , Marth C , Zeimet A G , Ulmer H , Zeillinger R & Concin N (2011)
      Br J Cancer 105, 1593-9

    • Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease
      Schwarzenbach H , Müller V , Milde-Langosch K , Steinbach B & Pantel K (2011)
      Mol Biosyst, 7, 2848-54

    • Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease.
      Schwarzenbach H, Müller V, Milde-Langosch K, Steinbach B, Pantel K. (2011)
      Mol Biosyst.7(10):2848-54.
    • Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer.
      Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U,Milde-Langosch K (2011)
      J Cancer Res Clin Oncol 137:1193-1201

    • Biological role of Activated Leukocyte Cell Adhesion Molecule (ALCAM) overexpression in breast cancer cell lines and clinical tumour tissue.
      Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K (2011).
      Breast Cancer Res Treatm 129(2):347-60
    • Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer .
      Wölber L, Kress K, Kersten JF, Choschzick M, Kilic E, Herwig U, Lindner C, Schwarz J, Jänicke F, Mahner S, Milde-Langosch K, Müller V, Ihnen M (2011)
      BMC Cancer 11:12
    • EGFR gene copy number increase in vulva carcinomas is linked with poor clinical outcome.
      Wölber L, Hess S, Bohlken H, Tennstedt P, Eulenburg C, Simon R, Gieseking F, Jänicke F, Mahner M, Choschzick M (2011)
      Journal of Clinical Pathology, Nov 29. [Epub ahead of print]
    • Serum Carbonic Anhydrase IX (CAIX) and its prognostic relevance in vulvar cancer
      Kock L, Mahner S, Choschzick M, Eulenburg C, Milde-Langosch K, Schwarz J,Jänicke F, Müller V, Wölber L (L.K. and S.M. contributed equally to this work) 2011:
      Int J Gynecol Cancer 21(1):141-8
    • HRT beim metabolischen Syndrom.
      Bühling KJ. (2011)
      Gynäkol Geburtsmed Gynäkol Endokrinol, in press.
    • Schilddrüse und Schwangerschaft.
      Bühling KJ. (2011)
      Seminar in Gynäkologischer Endokrinologie, in press.
    • Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly elevated ALCAM expression in metastases of the skin.
      Ihnen M, Kilic E, Köhler N, Löning T, Witzel I, Hagel C, Höller S, Kersten JF,Müller V, Jänicke F, Milde-Langosch K. (2011)
      J Clin Pathol 64, 146-52
    • Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer - a single-center experience
      Witzel I, Kantelhardt E, Milde-Langosch K, Ihnen M, Zeitz J, Harbeck N,Jänicke F, Müller V (2011) Onkologie 34(6):304-8
    • PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin / cyclophosphamide followed by paclitaxel and darbepoetin alfa in primary breast cancer - results at the time of surgery.
      Untch M, Fasching P, Koch F v, Conrad U, Fett W, Kurzeder C, Lück H -J, Stickeler E, Urbaczyk H, Liedtke B Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Loibl S, Minckwitz G v on behalf of the AGO PREPARE investigators (2011).
      Ann Oncol 22(9):1988-98
    • PREPARE trial A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin / cyclophosphamide followed by paclitaxel and darbepoetin alfa in primary breast cancer - long term results.
      Untch M, vMinckwitz G, Konecny G, Conrad U, Fett W, Kurzeder C, Lück H -J, Stickeler E, Urbaczyk H, Liedtke B, Beckmann M, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Loibl S, Fasching P on behalf of the AGO PREPARE investigators (2011)
      Ann Oncol 22(9):1999-2006
    • Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy Fourty one months median follow up data of the multicenter TECHNO trial
      Untch M, Fasching P, Konecny G, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta K, von Minckwitz G, Loibl S (2011)
      J Clin Oncol 29(25):3351-7
    • Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
      von Minckwitz G, Untch M, Nuesch E, Loibl S, Kaufmann M, Kummel S, Fasching P A, Eiermann W, Blohmer JU, Costa S D, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Juni P (2011)
      Breast Cancer Res Treat 125: 145-56
    • Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
      Loibl S, Müller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; GBG/AGO/NOGGO study groups (2011).
      Support Care Cancer 19(11):1789-95.
    • #133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
      Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N (2011).
      Br J Cance 105(10):1593-9
    • Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Karn T, Ruckhaberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gatje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A (2011)
      Breast Cancer Res Treat 130(2):409-20
    • Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
      Roth C, Pantel K, Müller V, Rack B, Janni W, Kasimir-Bauer S, Schwarzenbach H (2011)
      BMC Cancer 11: 4
    • Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
      Loibl S, Müller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; GBG/AGO/NOGGO study groups (2011).
      Support Care Cancer 19(11):1789-95.
    • Health-related quality of life and patient-defined benefit of clobetasol 0.05% in women with chronic lichen sclerosus of the vulva.
      Schwegler J, Schwarz J, Eulenburg C, Blome C, Ihnen M, Mahner S, Jänicke F, Augustin M, Wölber L (2011).
      Dermatology 223(2):152-60.
    • Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
      Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S(2011).
      Ann Oncol. 2011 Oct 5. [Epub ahead of print]
    • Malignant transformation of a serous borderline tumor and early metastasis of associated low-grade serous carcinoma detected on screening mammography.
      Rohsbach D, Trillsch F, Regier M, Choschzick M, Kommoss F, Hermsteiner M, Töllner T, Mattner UM, Jänicke F, Mahner S (2011)
      J Clin Oncol. 29(30):e763-5

    • Surgery for recurrent ovarian cancer.
      Heitz F, du Bois A, Kurzeder C, Pfisterer J, Barinoff J, Grabowski J, Hilpert F,Mahner S, Harter P (2011).
      Womens Health (Lond Engl). 7(5):529-35.
    • Clinical management of primary vulvar cancer.
      Wölber L, Kock L, Gieseking F, Petersen C, Trillsch F, Choschzick M, Jänicke F, Mahner S (2011).
      Eur J Cancer. 47(15):2315-21.
    • Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva.
      Wölber L, Choschzick M, Eulenburg C, Hager M, Jänicke F, Gieseking F, Kock L, Ihnen M, Petersen C, Schwarz J, Mahner S (2011).
      Ann Surg Oncol. 18(13):3811-8.
    • Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
      Mury D, Wölber L, Jung S, Eulenburg C, Choschzick M, Witzel I, Schwarz J,Jänicke F, Mahner S (2011).
      J Cancer Res Clin Oncol. 137(7):1131-7.
    • Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
      Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A (2011).
      Int J Gynecol Cancer. 21(2):289-95.
    • Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
      Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G (2011).
      J Clin Oncol. 29(2):242-8
    • Fetal development assessed by heart rate patterns-Time scales of complex autonomic control.
      Hoyer D, Nowack S, Bauer S, Tetschke F, Ludwig S, Moraru L, Rudoph A, Wallwitz U, Jänicke F, Haueisen J, Schleußner E, Schneider U (2011).
      Comput Biol Med. May 26. [Epub ahead of print]
    • Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
      Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jänicke F, Thomssen C, Harbeck N (2011).
      BMC Cancer. 11:140
    • Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
      Müller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimier-Bauer S, Zeitz J, Pantel K, Fehm T, Detect Study Group (2011)
      Cancer Res, Vol. 13: R71
    • A clinically relevant gene signature in triple negative and basal-like breast cancer.
      Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M (2011)
      Breast Cancer Res, Vol. 13: R97
    • A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
      Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kolbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M (2011)
      Clin Cancer Res 17(18):6012-20.
    • Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
      Karn T, Pusztai L, Ruckhaberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gatje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M (2011)
      Eur J Cancer, Jul 7 [Epub ahead of print]
    • Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
      Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, Rack B, Schneeweiss A, Fehm T (2011)
      Gyn Oncology 122(2):356-60
    • Adjuvante endokrine Therapie in der Postmenopause. Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome,
      Müller V, Stickeler E (2011)
      W. Zuckschwerdt Verlag 129-137
    • Nachweis zirkulierender Tumorzellen im Blut bei Patientinnen mit Mammakarzinom
      Müller V, Janni W, Fehm T (2011)
      Forum, Vol. 26: 45-46
    • Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
      Choschzick M, Oosterwijk E, Müller V, Wölber L, Simon R, Moch H, Tennstedt P (2011)
      Virchows Arch. 459(2):193-200.
    • Role of TP53 mutations in vulvar carcinomas.
      Choschzick M, Hantaredja W, Tennstedt P, Gieseking F, Wölber L, Simon R (2011)
      Int J Gynecol Pathol 30(5):497-504

    • Longitudinal analysis of changes in energy intake and macronutrient composition during pregnancy and 6 weeks post-partum.
      Talai Rad N, Wolf C, Wascher C, Henrich W, Siegmund T, Ritterath C, Heinze T, Siebert G, Bühling KJ. (2011)
      Arch Gynecol Obstet. 283:185-90
    • Einfluss des Geburtsmodus auf die sexuelle Aktivität der männlichen Partner. Ergebnisse einer Pilotstudie und Literaturübersicht.
      Awad O, Bühling KJ. (2011)
      Geburtsh Frauenheilk 71: 511-517

    • Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome
      Choschzick, M, Lassen, M P, Lebeau, A, Marx, A H, Terracciano, L, Heilenkötter, U, Jänicke, F, Bokemeyer, C, Izbicki, J, Sauter, G, Simon, R (2010):
      Modern Pathology 23(4):603-10

    • Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
      Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G (2010):
      J Clin Oncol Nov 29 [Epub ahead of print]
    • Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
      Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A (2010)
      Expert Rev Anticancer Ther 10(1):81-8
    • Comparison of pegfilgrastim on day 2 vs day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
      Loibl S, Müller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; On behalf of the GBG/AGO/NOGGO study groups Support Care Cancer 2010 Oct 16 (Epub ahead of print)
    • Biological role of Activated Leukocyte Cell Adhesion Molecule (ALCAM) overexpression in breast cancer cell lines and clinical tumour tissue
      Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel, K, Milde-Langosch K (2010)
      Breast Cancer Res Treatm, in press
    • A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer
      Sehouli, J, Camara, O, Mahner S, Bauknecht, T, Lichtenegger, W, Runnebaum, I, Look, K, Jänicke F, Oskay-Oezcelik,G (2010):
      Cancer Chemother Pharmacol 66(5):861-8
    • Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
      Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H (2010)
      Breast Cancer Res, Vol. 12: R90
    • Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
      Dose-Schwarz, J, Tiling, R, Avril-Sassen, S, Mahner S, Lebeau, A, Weber, C, Schwaiger, M, Jänicke F, Untch, M, Avril, N (2010):
      Br J Cancer 102(1): 35-41
    • Gene amplification in ductal carcinoma in situ of the breast
      Burkhardt, L, Grob, T J, Hermann, I, Burandt, E, Choschzick, M, Jänicke F, Müller, V, Bokemeyer, C, Simon, R, Sauter, G, Wilczak, W, Lebeau, A (2010):
      Breast Cancer Res Treatm 123(3):757-65
    • Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/MEDM) in primary breast carcinoma and distant breast cancer metastasis
      Ihnen M, Köhler, N, Kersten, J F, Milde-Langosch K, Beck K, Höller S, Müller V, Witzel I, Jänicke F, Kilic, E (2010)
      Dis Markers 28: 71-78
    • Combination of Osteopontin and Activated Leukocyte Cell Adhesion Molecule as potent prognostic discriminators in HER2 and ER negative breast cancer
      Ihnen, M, Wirtz, R M, Kalogeras, K T, Milde-Langosch, K, Schmidt, M, Witzel, I, Eleftheraki, A G, Papadimitriou, C, Jänicke, F, Briassoulis, E, Pectasides, D, Rody, A, Fountzilas, G, Müller, V (2010)
      Brit J Cancer 103: 1048-56
    • TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
      Mahner, S, Woelber, L, Eulenburg, C, Schwarz, J, Carney, W, Jänicke, F, Milde-Langosch, K, Müller, V (2010)
      BMC Cancer 10: 139
    • The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells
      Schröder, C, Schumacher, U, Müller, V, Wirtz, R M, Streichert, T, Richter, U, Wicklein, D, Milde-Langosch, K (2010)
      Eur J Cancer 46: 1650-1660
    • Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome
      Witzel, I D, Milde-Langosch, K, Wirtz, R M, Roth, C, Ihnen, M, Mahner, S, Zu Eulenburg, C, Jänicke, F, Müller, V (2010)
      J Cancer Res Clin Oncol 136(11):1709-18
    • Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
      Konecny, G E, Pauletti, G, Untch, M, Wang, H J, Möbus, V, Kuhn, W, Thomssen, C, Harbeck, N, Wang, L, Apple, S, Jänicke, F, Slamon, D J (2010)
      Breast Cancer Res Treat 20(2):481-9
    • Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group
      Eiermann, W, Graf, E, Ataseven, B, Conrad, B, Hilfrich, J, Massinger-Biebl, H, Vescia, S, Loibl, S, von Minckwitz, G, Schumacher, M, Kaufmann, M, German Adjuvant Breast Cancer Group (2010)
      Eur J Cancer 46(1):84-94
    • Clinical management of borderline ovarian tumors
      Trillsch F, Mahner S, Ruetzel, J, Harter, P, Ewald-Riegler, N, Jänicke, F, du Bois, A (2010)
      Expert Rev Anticancer Ther 10(7):1115-24
    • Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer
      Wölber L, Jung, S, Eulenburg, C, Müller V, Schwarz, J, Jänicke F, Mahner S (2010)
      Eur J Surg Oncol 36(6):583-8

    • Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases
      Choschzick, M, Wölber, L, Hess, S, zu Eulenburg, C, Schwarz, J, Simon, R,Mahner, S, Jänicke, F, Müller, V (2010)
      Virchows Arch 456(5):483-90
    • Serum carbonic anhydrase IX during first-line therapy of ovarian cancer
      Wölber, L, Müller, V, Eulenburg, C, Schwarz, J, Carney, W, Jänicke, F, Milde-Langosch, K, Mahner, S (2010)
      Gynecol Oncol 117(2):183-8
    • Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer
      Choschzick, M, Lebeau, A, Marx, A H, Tharun, L, Terracciano, L, Heilenkötter, U, Jänicke, F, Bokemeyer, C, Simon, R, Sauter, G, Schwarz, J (2010)
      Hum Pathol 41(3):358-65
    • HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
      Fehm, T, Müller, V, Aktas, B, Janni, W, Schneeweiss, A, Stickeler, E, Lattrich, C, Löhberg, C R, Solomayer, E, Rack, B, Riethdorf, S, Klein, C, Schindlbeck, C, Brocker, K, Kasimir-Bauer, S, Wallwiener, D, Pantel, K (2010)
      Breast Cancer Res Treat Sep 22 [Epub ahead of print]
    • Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer
      Müller, V, Thomssen, C, Schmidt, M, Glados, M, Jackisch, C, Heilmann, V, Hinke, A, Lehnert, A, Borowicz, H, Möbus, V (2010)
      BMC Cancer 16;10:430
    • Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
      Witzel, I, Loibl, S, von Minckwitz, G, Mundhenke, C, Huober, J, Hanusch, C, Henschen, S, Hauschild, M, Lantzsch, T, Tesch, H, Latos, K, Just, M, Hilfrich, J, Barinoff, J, Eulenburg, C, Roller, M, Untch, M, Müller, V (2010)
      Breast Cancer Res Treat 123(2):437-45
    • Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies
      Lebeau, A, Turzynski, A, Braun, S, Behrhof, W, Fleige, B, Schmitt, W D, Grob, T J, Burkhardt, L, Hölzel, D, Jackisch, C, Thomssen, C, Müller V, Untch, M (2010)
      J Clin Oncol 28(20):3264-70
    • Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
      Riethdorf, S, Müller V, Zhang, L, Rau, T, Loibl, S, Komor, M, Roller, M, Huober, J, Fehm, T, Schrader, I, Hilfrich, J, Holms, F, Tesch, H, Eidtmann, H, Untch, M, von Minckwitz, G, Pantel, K (2010)
      Clin Cancer Res 16(9):2634-45
    • Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies
      Müller, V, Alix-Panabières, C, Pantel, K (2010)
      Eur J Cancer 46(7):1189-97
    • First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial
      Untch, M, Muscholl, M, Tjulandin, S, Jonat, W, Meerpohl, H G, Lichinitser, M, Manikhas, A G, Coumbos, A, Kreienberg, R, du Bois, A, Harbeck, N, Jackisch, C, Müller V, Pauschinger, M, Thomssen, C, Lehle, M, Catalani, O, Lück, H J (2010)
      J Clin Oncol 28(9):1473-80
    • Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data
      Ruckhäberle, E, Karn, T, Engels, K, Turley, H, Hanker, L, Müller V, Schmidt, M, Ahr, A, Gaetje, R, Holtrich, U, Kaufmann, M, Rody, A (2010)
      Eur J Cancer 46(3):549-57
    • Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
      Sehouli, J, Pietzner, K, Harter, P, Münstedt, K, Mahner S, Hasenburg, A, Camara, O, Wimberger, P, Boehmer, D, Bühling, K J, Richter, R, El Khalfaoui, K, Oskay-Ozcelik, G (2010)
      Ann Oncol May 3 [Epub ahead of print)
    • Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer - a single-center experience
      Witzel, I, Kantelhardt, E, Milde-Langosch, K, Ihnen, M, Zeitz, J, Harbeck, N,Jänicke, F, Müller, V (2010)
      Onkologie, in press
    • Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies Lebeau, A, Turzynski, A, Braun, S, Behrhof, W, Fleige, B, Schmitt, W D, Grob, T J, Burkhardt, L, Holzel, D, Jackisch, C, Thomssen, C, Müller, V, Untch, M (2010)
      J Clin Oncol 28: 3264-3270
    • Prognostische und prädiktive Faktoren (unter Berücksichtigung von Genexpressionsanalysen) Mammakarzinom Interdisziplinär
      Jänicke, F, Müller, V, Harbeck, N (2010)
      Springer Academic Press, 98-109, (Book chapter)
    • Adjuvante Chemo- und Antikörpertherapie des Mammakarzinoms CME Praktische Fortbildung Gynäkologie
      Müller, V, Stickeler, E (2010)
      Geburtshilfe und Gynäkologische Endokrinologie 6: 68-79
    • ASCO 2010 - Highlights aus der Gynäkoonkologie
      Fehm, T, Müller, V, Hartkopf, M, Schmidt, M, Becker, S (2010)
      Frauenarzt 51: 730-735
    • News from the San Antonio Breast Cancer Symposium 2009
      Untch, M, Bauerfeind, I, Jackisch, C, Kühn, T, Müller, V (2010)
      Breast Care 5: 38-43

    • New Developments in Breast Cancer Therapy Presented at ASCO 2010
      Müller, V, Dubsky, P, Fehm, T, Fitzal, F, Houber, J, Schmidt, M, Steger, G (2010)
      Breast Care 5: in press
    • Advantages and Challenges of Oestrogen-Free Hormonal Contraception
      Ahrendt HJ, Bühling KJ (2010)
      Curr Med Res Opin 26:1947-55
    • Role of Secondary Cytoreductive Surgery in Ovarian Cancer Relapse: Who Will Benefit? A Systematic Analysis of 240 Consecutive Patients
      Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C (2010)
      J Surg Oncol 102:656-62
    • Longitudinal analysis of changes in energy intake and macronutrient composition during pregnancy and 6 weeks post-partum
      Talai Rad N, Wolf C, Wascher C, Henrich W, Siegmund T, Ritterath C, Heinze T, Siebert G, Bühling KJ
      Arch Gynecol Obstet in press
    • Väter im Kreißsaal Ergebnisse einer Umfrage
      Awad O, Bühling KJ
      Geburtsh Frauenheilk in press
    • Schilddrüse und Schwangerschaft
      Bühling KJ (2010)
      Gynakol Geburtsmed Gynäkol Endokrinol 6:44-56
    • Estrogen free contraception: Progestin-only-systems
      Ahrendt HJ, Bühling KJ (2010)
      J Reproduktionsmed Endokrinol 7: 97-105
    • Advantages and Challenges of Oestrogen-Free Hormonal Contraception.
      Ahrendt HJ, Bühling KJ. (2010)
      Curr Med Res Opin. 26:1947-55
    • Role of Secondary Cytoreductive Surgery in Ovarian Cancer Relapse: Who Will Benefit? A Systematic Analysis of 240 Consecutive Patients.
      Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C. (2010)
      J Surg Oncol.102:656-62.
    • Schilddrüse und Schwangerschaft.
      Bühling KJ. (2010)
      CME Prakt Fortbild Gynakol Geburtsmed Gynäkol Endokrinol 20 6:44-56
    • Estrogen free contraception: Progestin-only-systems.
      Ahrendt HJ, Bühling KJ. (2010)
      J. Reproduktionsmed. Endokrinol 7: 97-105

    • HRT beim metabolischen Syndrom.
      Bühling KJ.(2010)
      CME Prakt Fortbild Gynakol Geburtsmed Gynakol Endokrinol 2010; 6: 172-184

    • Adjuvante Chemotherapie und Antikörpertherapie Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome
      Müller V, Stickeler E
      Zuckerschwerdt Verlag, Seite 23-40 (2009)

    • Prognostic factors for complete debulking in first- and second-line ovarian cancer
      Harter, P, Hilpert, F, Mahner, S, Kommoss, S, Heitz, F, Pfisterer, J, du Bois, A
      Int J Gynecol Cancer Suppl 2:S14-7 (2009)
    • Clinical Relevance of Disseminated Tumor Cells in Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients
      Müller V, Janni W, Gebauer G, Solomayer E, Janni W, Pantel K
      Breast Care, Vol 4: 333-338 (2009)
    • HER2 as marker for the detection of circulating tumor cells
      Müller V, Pantel K
      Breast Cancer Res Treat, Vol 117: 535-7 (2009)
    • Neue Perspektiven für die Therapie des Ovarialkarzinoms
      Harter P, Hilpert F, Mahner S, Pfisterer J, du Bois A (2009)
      Gyn Spectrum 2009 Sep; 3
    • Expression and prognostic value of L1-CAM in breast cancer
      Schroder C, Schumacher U, Fogel M, Feuerhake F, Müller V, Wirtz R M, Altevogt P, Krenkel S, Jänicke F, Milde-Langosch K
      Oncol Rep, Vol 22: 1109-17 (2009)
    • Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens
      Thomssen C, Harbeck N, Dittmer J, Abraha-Spaeth SR, Papendick N, Paradiso A, Lisboa B, Jänicke F, Schmitt M, Vetter M
      J Natl Cancer Inst 2009 101 (14): 1028-1029 (2009)
    • HER-2/neu analysis in breast cancer bone metastases
      Zustin J, Boddin K, Tsourlakis MC, Burandt E, Mirlacher M, Jänicke F, Izbicki J, Ruether W, Rueger JM, Bokemeyer C, Simon R, Sauter G
      J Clin Pathol 62(6):542-6 (2009)
    • Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer
      Wölber L, Mahner S, Voelker K, Eulenburg CZ, Gieseking F, Choschzick M,Jänicke F, Schwarz J
      Anticancer Res 29(2):545-52 (2009)
    • Expression and prognostic value of Activating Transcription Factor 2 (ATF2) and its phosphorylated form in mammary carcinomas
      Knippen S, Löning T, Müller V, Schröder C, Jänicke F, Milde-Langosch K
      Anticancer Res 29, 183-90 (2009)
    • Expression of Jun and Fos proteins in ovarian tumors of different invasive potential and ovarian cancer cell lines
      Hein S, Mahner S, Tirok C, Löning T, Jänicke F, Milde-Langosch K
      Oncology Rep 22, 177-83 (2009)
    • Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
      Rody A, Karn T, Ruckhaberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M
      Breast Cancer Res Treat 113, 457-66 (2009)
    • Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential FDG-PET Imaging
      Dose-Schwarz J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jänicke F, Avril N
      J Clin Oncol 27(4):535-41 (2009)
    • Intensive dose dense compared with conventionally scheduled preoperative chemotherapy for high risk primary breast cancer
      Untch M, Möbus V, Kuhn W, Muck, BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweis A, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny G
      J Clin Oncol 27(18):2938-45 (2009)
    • Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study
      Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology
      Cancer Chemother Pharmacol 64(3):585-91 (2009)
    • Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine
      Barthell E, Wölber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings HL, Railkar R, Gause C, Barr E
      Arch Gynecol Obstet 279(6): 803-7 (2009)
    • German Expert Opinion on the St Gallen Votes on March 2009 (11th International Conference at St Gallen: Primary Therapy of Early Breast Cancer)
      Beckmann MW, Blohmer J-W, Costa S-D, Diedrich K, Diel I, Eiermann W, Friese K, Gerber B, Harbeck N, Hilfrich J, Janni W, Jänicke F, Jonat W, Kaufmann M, Kiechle M, Koehler U, Kreienberg R, von Minckwitz G, Moebus V, Nitz U, Schneeweiss A, Thomssen C Wallwiener, D Zurich Konsensus
      Breast Care 4: 109-116 (2009)
    • Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction
      Mahner S, Wölber L, Jung S, Eulenburg zu C, Ihnen M, Schwarz, Sehouli, J,Jänicke F
      Anticancer Res 29: 2817-2822 (2009)
    • Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR)
      Pölcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Höss C, Leutner C, Braun M, Möbus V, Karbe I, Stimmler P, Rudlowski C, Schwarz J, Kuhn W
      Oncol Rep 22(3):605-13 (2009)
    • Role of cytoreductive surgery in recurrent ovarian cancer
      Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A
      Expert Rev Anticancer Ther 9(7):917-22 (2009)
    • Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers - Results of a large scale microarray analysis
      Rody A, Karn T, Ruckhaberle E, Hanker L, Metzler D, Müller V, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M
      Eur J Cancer, 5: 405 - 413, 2009
    • Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18 F]fluorodeoxyglucose
      Schwarz-Dose, J, Untch, M, Tiling, R, Sassen, S, Mahner, S, Kahlert, S, Harbeck, N, Lebeau, A, Brenner, W, Schwaiger, M, Jänicke, F, Avril, N
      J Clin Oncol 27: 535-541, 2009
    • Zurich Konsensus: German Expert Opinion on the St Gallen Votes on March 2009 (11th International Conference at St Gallen: Primary Therapy of Early Breast Cancer)
      Beckmann, M W, Blohmer, J -W, Costa, S -D, Diedrich, K, Diel, I, Eiermann, W, Friese, K, Gerber, B, Harbeck, N, Hilfrich, J, Janni, W, Jänicke, F, Jonat, W, Kaufmann, M, Kiechle, M, Koehler, U, Kreienberg, R, v Minckwitz, G, Moebus, V, Nitz, U, Schneeweiss, A, Thomssen, C, Wallwiener, D
      Breast Care 2009: 4: 109-116, 2009
    • Why use of dienogest for the first contraceptive pill with estradiol?
      Mueck AO, Seeger H, Bühling KJ. (2009)
      Gynecol Endocrinol 11:1-5
    • Gynäkologische und geburtshilfliche Komplikationen bei Frauen mit Adipositas.
      Bühling KJ. (2009)
      Akt Ernähr Med 34: 126-130
    • Adipositas und Schwangerschaft: Gynäkologische und geburtshilfliche Komplikationen.
      Awad O, Bühling KJ.(2009)
      AdipositasSpektrum 5:13-17

    • Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.
      Milde-Langosch K, Janke S, Wagner I, Schröder C, Streichert T, Bamberger A-M, Jänicke F, Löning T.
      Breast Cancer Res Treatm 107, 337-47 (2008).

    • Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
      Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N,Dose-Schwarz J.
      Ann Oncol. 19, 1249-54 (2008).

    • Trastuzumab (Herceptin®) Therapy During Pregnancy associated with Poor Fetal Outcome.
      Witzel, I., Müller, V., Jänicke, F., Harps, E., and deWit, M.
      Ann Oncol, 19, 191-192, 2008.

    • The similarities of aromatase inhibitors outweigh the differences.
      Jänicke, F.
      Anti Cancer Drugs 19: Suppl 2, S7-S9 (2008).

    • Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
      Ihnen, M., Müller, V., Wirtz, R.M., Schröder, C., Krenkel, S., Witzel, I., Lisboa, B.W., Jänicke, F., Milde-Langosch, K.
      Breast Cancer Res Treat 112, 419-27 (2008).

    • Multicenter study using paraffin-embedded tumor tissue validates PITX2 DNA methylation for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
      Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Kluth A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R, on behalf of the EpiBreast Group. J Clin Oncol 26, 5036-42 (2008).

    • Detection of metastases in breast cancer patients.
      Dose-Schwarz J, Mahner S, Schirrmacher S, Jenicke L, Müller V, Habermann CR, Brenner W
      Nuklearmed. 473, 97-103 (2008).

    • Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study.
      Hillemanns P, Gabrielle Breugelmans J, Gieseking F, Bénard S, Lamure E, Littlewood KJ, Petry KU.
      BMC Infectios Diseases 8:76 (2008).

    • Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
      Fehm T, Müller V, Alix-Panabieres, Pantel K.
      Breast Can Res 10, Suppl. 1: S1 (2008).

    • A comparative study of tissue inhibitor of metalloproteinase-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
      Schrohl AS, Müller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N.
      Tumour Biol 29: 181-7 (2008).

    • Chemoendocrine treatment is standard in hormone receptor positive patients.
      Müller V.
      Breast Care 3: 229-230 (2008).

    • Detection of minimal residual disease in predicting outcome.
      Müller V, Panabieres C, Pantel K.
      Prognostic and predictive factors in breast cancer, Informa Healthcare, 88-96 (book-chapter), 2008.

    • Tumor cell dormancy: implications for the biology and treatment of breast cancer.
      Fehm T, Müller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E, Becker S.
      Apmis 116: 742-53 (2008).

    • C-Fos expression is a Molecular Predictor of Progression and Survival in Epithelian Ovarian Carcinoma.
      Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K.
      Br J Cancer 99: 1269-75 (2008).

    • The Efficacy of Clobetasol 0.05% for Treatment of Vulvar Lichen Sclerosus.
      Schwarz J, Schwegler J, Augustin M, Ihnen M, Mahner S, Wölber L.
      Geburtsh Frauenheilk 68: 615-619 (2008).

    • Mammakarzinom.
      Avril N, Bienert M, Dose-Schwarz J.
      Nuklearmedizinische Onkologie. Hrsg: Krause-Buck-Schwaiger; Ecomed Medizin Verlag, 241-257 (2008).

    • PET & PET/CT: Ovarialkarzinom.
      Bienert M, Dose-Schwarz J, Avril N.
      Nuklearmedizinische Onkologie. Hrsg: Krause-Buck-Schwaiger; Ecomed Medizin Verlag, 257-267 (2008)

    • Evidenzbasierte Therapie der Nausea und (Hyper)Emesis gravidarum.
      Bühling KJ, David M.
      CME Prakt Fortb Gynakol Geburtsmed Gynäkol Endokrinol 2008.

    • Longitudinal changes of the Continuous Glucose Monitoring Profile in pregnant patients.
      Siegmund T, Ritterath C, Wascher C, Talai Rad N, Siebert G, Henrich W,Bühling KJ.
      Eur J Obstet Gynecol R B 139:46-52 (2008).

    • Fettstoffwechselstörungen in der Schwangerschaft - eine wenig beachtete Komplikation.
      Bühling KJ.
      Dtsch med Wochenschr 133: 2177 (2008).

    • Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
      Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D.
      Brit J Cancer 99: 930-38 (2008).

    • Clinical significance of p53 alterations in surgically treated prostate cancers.
      Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A.
      Mod Pathol 21(11): 1371-8 (2008).

    • Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.
      Briese J, Schulte HM, Sajin M, Bamberger C, Redlin K, Milde-Langosch K, Löning T, Bamberger AM.
      Virchows Arch 453(1): 89-96 (2008).

    • Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
      Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terraciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R.
      Nature Genetics 39: 655-660, 2007

    • Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
      Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J,Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle RJ, Meissner H, Müller RT, Pawlita M, Petry KU, Pilch H, Walek E, Schneider A.
      Int J Cancer. 121:2794-800, 2007.

    • Continuing with letrozole offers greater benefits.
      Jänicke, F.
      J Cancer Res Clin Oncol 133: 445-453, 2007

    • Current treatment options in uterine stromal sarcoma: report of a case and review of the literature.
      Ihnen, M., Mahner, S., Jänicke, F., Schwarz, J.
      Int J Gynecol Cancer 17: 957-963, 2007

    • Ulex europaeus agglutinin-I binding as a potential prognostic marker in ovarian cancer.
      Blonski K, Milde-Langosch K, Bamberger A-M, Osterholz T, Utler C, Berger J, Löning T, Schumacher U.
      Anticancer Res 27: 2785-90, 2007

    • Invasionsfaktoren uPA/PAI-1 im Tumorgewebe bei Patientinnen mit primärem Mammakarzinom: Von Forschungsergebnissen zur klinischen Anwendung am Beispiel der NNBC 3-Europe-Studie
      Vetter M, Kantelhardt EJ, Annecke K, Dittmer J, Paepke D, Prechtl A, Schmitt M,Jänicke F, Minckwitz G, Kiechle-Barat M, Thomssen C, Harbeck N.
      Geburtsh Frauenheilk 67: 1144-1152, 2007

    • Good agreement between physician and self-reported hormone therapy data in a case-control study.
      Kropp S, Terboven T, Hedicke J, Mutschelknauss E, Slanger T, Braendle W, Berger J, Chang-Claude J, Flesch-Janys D.
      J Clin Epidemiol 60: 1280-7, 2007

    • Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy.
      Slanger T, Mutschelknauss E, Kropp S, Braendle W, Flesch-Janys D, Chang-Claude J.
      Ann Epidemiol 17: 993-8, 2007

    • Recommendations for hormonal contraception. 36th Professional Meeting of the "Zurich Discussion Group", April 2006.
      Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Gynakol Geburtshilfliche Rundsch 47: 94-8, 2007

    • Recommendations for estrogen and progesterone substitution in climacteric and postmenopause.
      Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Gynakol Geburtshilfliche Rundsch 47: 45-8, 2007

    • Detection of disseminated tumor cells in the bone marrow and blood of breast cancer patients.
      Müller V., Pantel K.
      In: Metastasis of Breast Cancer, Springer Academic press, 116-127, 2007.

    • Tumorzellnachweis im Knochenmark und Blut von Patientinnen mit Mammakarzinom: Klinisches Potenzial, Studienergebnisse und aktuelle Forschungsprojekte in Deutschland.
      Müller V., Pantel K., Riethdorf S., Schindlbeck C., Rack B., Solomayer E., Janni W., Fehm T.
      Geburtshilfe Frauenheilkunde, 67: 717-720, 2007.

    • Asservierung von Biomaterialien für translationale Fragestellungen im Rahmen aktueller Brustkrebsstudien. Überblick und Empfehlungen.
      vMinckwitz G., Arnold N., Denkert C., Dittmer J., Fehm T., Harbeck N., Janni W., Meinhold-Heerlein I., Müller V., Pantel K., Rody A., Schmitt M.
      Geburtshilfe Frauenheilkd, Vol. 67: 451-459, 2007.

    • Der Nachweis von isolierten Tumorzellen in Knochenmark und Blut von Patientinnen mit primärem Mammakarzinom - Standardisierte Methodik und klinische Relevanz.
      Janni W., Fehm T., Rack B., Müller V., Solomayer E., Schindlbeck C., Jückstock J., Pantel K., Wallwiener D., Friese K.
      Senologie, Vol. 4: 92-98, 2007.

    • DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients - Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
      Maier S., Nimmrich I., Koenig T., Eppenberger-Castori S., Bohlmann I., Paradiso A., Spyratos F., Thomssen C., Müller V., Nährig J., Schittulli F., Kates R., Lesche R., Schwope I., Kluth A., Marx A., Martens J.W., Foekens J.A., Schmitt M., Harbeck N.
      Eur J Cancer, Vol. 43: 1679-1686, 2007.

    • Die klinische Bedeutung des Nachweises von isolierten Tumorzellen im Knochenmark und peripheren Blut von Patientinnen mit primärem Mammakarzinom.
      Janni W., Fehm T., Rack B., Müller V., Solomayer E., Stickeler E., Sommer H., Schindlbeck C., Jückstock J., Friese K.
      Geburtshilfe Frauenheilkd, Vol. 67: 653-660, 2007.

    • Isolierte Tumorzellen in Knochenmark und Blut von Patientinnen mit Mammakarzinom - Klinische Relevanz.
      Janni W., Fehm T., Rack B., Müller V., Solomayer E., Pantel K., Sommer H., Schindlbeck C., Jückstock J., Friese K.
      Der Gynäkologe, Vol. 40: 431-439, 2007.

    • Detection and characterization of putative metastatic precursor cells in cancer patients.
      Alix-Panabières, C., Vendrell, J.-P., Pellé, O., Riethdorf, S., Müller, V., Fabbro, M., Pantel, K.
      Clin Chem 53: 537-539, 2007

    • Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System.
      Riethdorf S., Fritsche H., Müller V., Rau T., Schindlbeck C., Rack B., Janni W., Coith C., Beck K., Jänicke F., Jackson S., Gornet T., Cristofanilli M., Pantel K.
      Clin Cancer Res 13: 920-928, 2007

    • Nachweis disseminierter Tumorzellen in Knochenmark von Patientinnen mit primärem Mammakarzinom.
      Fehm T., Müller V., Janni W., Braun S., Gebauer G., Marth C., Schindlbeck C., Wallwiener D., Borgen E., Pantel K., Solomayer E.
      Frauenarzt 48: 120-126, 2007

    • Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time ofmetastatic disease by serum HER2 and HER2 status of circulating tumor cells.
      Fehm T., Becker S., Duerr-Stoerzer S., Sotlar K., Müller V., Wallwiener D., Lane N., Solomayer E., Uhr J.
      Breast Can Res, Oct 26;9(5):R74 [Epub ahead of print]

    • A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
      Schwarzenbach H., Müller V., Beeger C., Gottberg M., Stahmann N., Pantel K.
      Breast Can Res, 2007 Oct 3;9(5):R66 [Epub ahead ofprint]

    • Current status in human breast cancer micrometastasis.
      Panabières C., Müller V., Pantel K.
      Curr Opin Oncol, Vol. 19: 558-563, 2007.

    • Cox-2 is a target gene of Rho GDP dissociation inhibitor ß in breast cancer cells.
      Schunke D., Span P.N., Ronneburg H., Dittmer A., Vetter M., Holzhausen H.J., Kantelhardt E., Krenkel S., Müller V., Sweep F., Thomssen C., Dittmer J.
      Cancer Res, Vol. 67:10694-702, 2007.

    • Potential clinical utility of HER-2/neu extracellular domain and soluble EGFR fragments determined in serum of metastatic breast cancer patients.
      Witzel I, Thomssen C, Krenkel S, Wilczak W, Bubenheim M, Pantel K, Neumann R, Jänicke F, Müller V.
      Intern J Biol Markers 21: 2006

    • Prognostic and predictive impact of Epidermal Growth Factor Receptor (EGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
      Müller V, Witzel I, Wilczak W, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Löning T, Jänicke F, Thomssen C.
      Anticancer Res 26: 1479-1488, 2006

    • A concept for the standardized detection of disseminated tumor cells in bone marrow of patients with primary breast cancer and its clinical implementation.
      Fehm T, Braun S, Müller V, Janni W, Marth C, Pantel K, Schindlbeck C, Solomayer E.
      Cancer 107: 885-892, 2006

    • The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity.
      Schrepfer S, Deuse T, Munzel T, Schafer H, Braendle W, Reichenspurner H.
      Menopause. 13(3):489-99, 2006

    • Empfehlungen zur hormonalen Kontrazeption [Recommendations for hormonal contraception. 34. Workshop of the "Zürich Discussion Circle", April 2005].
      Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Gynäkol Geburtshilfliche Rundsch 46 (1-2):58-63, 2006

    • Empfehlungen zur Substitution mit Östrogenen und Gestagenen im Klimakterium und in der Postmenopause [Recommendations for estrogen and progesterone replacement in climacteric and postmenopause. 33. Workshop of the "Zürich Discussion Circle", October 2004.]
      Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Gynäkol Geburtshilfliche Rundsch. 46(1-2):53-7, 2006

    • Recent translational research: Circulating tumor cells in breast cancer patients.
      Müller V      , Hayes D, Pantel K.
      Breast Cancer Res 8: 110, 2006

    • Tumor cell dissemination and metastasis in breast cancer: Selected presentations at the 28th San Antonio Breast Cancer Symposium 2005.
      Müller V      , Stickeler E.
      Breast Care 1: 113-116, 2006

    • Metastasierungsmechanismen beim Mammakarzinom.
      Müller V      , Pantel K, Stickeler E.
      Frauenarzt 47: 822-824, 2006

    • Disseminated Tumor Cells in Breast Cancer: Detection, Characterization and Clinical Relevance.
      Woelfle U, Müller V, Pantel K.
      Future Oncology 2: 553-561, 2006

    • Management of skin-sparing mastectomy: results of a survey of German hospitals.
      Dian D, Hemminger G, Janni W, Friese K, Jänicke F.
      Onkologie 29(6): 267-70 2006

    • Regression von Condylomata acuminata in der Schwangerschaft nach systemischer Therapie mit Thuja.
      Ihnen M, Mahner S, Schwarz J      .
      Geburtsh Frauenheilk 66: 179-182, 2006

    • Operative Therapie des fortgeschrittenen Ovarialkarzinoms. Ergebnisse aus der Klinik für Gynäkologie des UKE aus den Jahren 1996-2001.
      Schwarz J, Utler C      , Yekebas E, Jänicke F.
      Hamburger Ärzteblatt 1/06: 6-9, 2006

    • BRCA1-IRIS regulates Cyclin D1 Expression in Breast Cancer Cells.
      Nakuci E, Mahner S, DiRenzo J, ElShamy WM.
      Exp Cell Res 312(16):3120-31, 2006

    • Krankheiten der Adnexe.
      Schwarz J, Mahner S, Jänicke F      .
      In: Die Gynäkologie. Kaufmann, M; Costa, SD; Scharl, A (Hrsg.). 2., überarb. Aufl., 2006

    • Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
      Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Zander AR, Löning T.
      Clin Cancer Res 12: 159-68, 2006

    • Prognostische und prädiktive Faktoren bei Patientinnen mit Mammakarzinom. In: Management des Mammakarzinoms.
      Müller V., Jänicke F.
      Springer Verlag. 183-198, 2006

    • Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity.
      Müller V      , Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Jänicke F, Pantel K
      Clin Cancer Res 11: 3678-3685, 2005

    • Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients.
      Woelfle U, Breit E, Zafrakas K, Otte M, Schubert F, Müller V, Izbicki JR, Löning T, Pantel K
      J Immunol Methods 300: 136-45, 2005

    • The phytoestrogen biochaninA weakens acute cardiac allograft rejection without affecting the reproductive system.
      Schrepfer S, Deuse T, Schafer H, Koch-Nolte F, Braendle W, Reichenspurner H.
      Transpl Immunol. 15(1):45-53, 2005

    • Systemic therapy of operable carcinoma of the breast.
      Kaufmann M, Jonat W, Eiermann W, Costa S, Hilfrich J, Jänicke F, Beckmann MW, Wallwiener D, Gerber B, Rody A, Schneeweiss A, Nitz U, Köhler U, von Minckwitz G.
      Zentralbl Gynäkol. 127(4):207-12, 2005

    • Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
      Dose Schwarz J, Bader M, Jänicke L, Hemminger G, Jänicke F, Avril N.
      J Nucl Med. 46(7):1144-50, 2005

    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
      Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.
      N Engl J Med. 353(16):1659-7, 2005

    • Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.
      Von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N, Vermorken JB, Loibl S, Merkle Kh, Kaufmann M.
      Anticancer Drugs. 16(8):871-7, 2005

    • Bone marrow micrometastases and circulating tumor cells in breast cancer patients: Where have we been, where are we now and where does the future lie?
      Müller V, Pantel K.
      Cytotherapy 7: 478-482, 2005

    • St. Gallen 2005: Konsens und klinische Praxis.
      Jänicke F, Diedrich K, Jonat W, Gerber B, Lisboa B, Friedrich M, Reimer T, Maas N.
      Frauenarzt 46, 182-189, 2005

    • Die Bedeutung der radikalen zytoreduktiven Chirurgie für die Überlebenszeit von Patientinnen mit fortgeschrittenem Ovarialkarzinom.
      Utler C, Osterholz T, Dose Schwarz J, Thomssen C, Jänicke F.
      Geburtsh Frauenheilk 65: 1168-1177, 2005

    • Diagnostische Mammographie und Sonographie: Korrelation von diagnostischer BI-RADS-Einstufung mit dem histologischen und klinischen Endbefund [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome]
      Lorenzen J, Wedel AK, Lisboa BW, Löning T, Adam G.
      Röfo. 177(11):1545-51, 2005

    • Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer.
      Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, Löning T.
      Br J Cancer 92: 2206-2215, 2005

    • Empfehlungen zur Hormonsubstitution in Klimakterium und Postmenopause. 33. Arbeitstreffen des Zürcher Gesprächskreises Oktober 2004.
      Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Frauenarzt 46: 194-197, 2005

    • Langzyklus.
      Braendle W.
      Gynäkologische Endokrinologie 2, 131-133 (2005)

    • Benigne und maligne Tumoren unter hormonaler Kontrazeption. 34. Treffen Zürcher Gesprächskreis.
      Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J:
      Frauenarzt 46: 2-4, 2005

    • Das Klimakterium.
      Braendle W:
      Zweite Auflage. Wissenschaftliche Verlagsgesellschaft Stuttgart (2005)

    • Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
      Schwarzenbach H, Müller V, Stahmann N, Pantel K.
      Ann N Y Acad Sci 1022: 25-32, 2004
    • Sentinel Lymph Node Dissection and Micrometastasis Detection in Bone Marrow and Lymph Nodes.
      Müller V, Kasimir-Bauer S, Pantel K.
      Molecular Oncology of Breast Cancer, Jones and Bartlett, 117-127, 2004

    • Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
      Müller V, Witzel I, Lück H, Köhler G, v. Minckwitz G, Möbus V, Sattler D, Löning T, Wilczak W, Jänicke F, Pantel K, Thomssen C.
      Breast Cancer Res Treat 86: 9-18, 2004

    • Laparoscopic oophoropexy for the treatment of recurrent torsion of the adnexa in pregnancy: case report and review.
      Djavadian D, Braendle W, Jänicke F.
      Fertil Steril. 82(4):933-6, 2004

    • Die Zystektomie aus anderer Indikation als dem Blasenkarzinom [Cystectomy for indications other than bladder cancer].
      Hautmann S, Felix-Chun KH, Currlin E, Friedrich MG, Dose Schwarz J, Langwieler T, Conrad S, Huland H.
      Urologe A. 43(2):172-7, 2004

    • Empfehlungen zur Substitution mit Östrogenen und Gestagenen im Klimakterium und in der Postmenopause [Recommendations for estrogen and progestin replacement therapy in climacteric and postmenopause. 31. Professional Meeting of the Zürich Discussion Circle, October 2003]
      Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Gynäkol Geburtshilfliche Rundsch. 44(4):258-64, 2004

    • Are all aromatase inhibitors the same? A review of the current evidence.
      Jänicke F.
      Breast 13 Suppl 1:S10-8. Review. 2004

    • Operative Therapie des Ovarialkarzinoms.
      Jänicke F.
      Gynäkologe 10 : 916-928, 2004

    • Recent advances in the treatment of breast cancer (Editorial).
      Smith IE, Jänicke F.
      The Breast 13: S1-S2, 2004

    • How important is c-erb B2 or Her-2/neu when deciding on which therapy?
      Lisboa BW, Jänicke F.
      EJC Supplements (2) 9: 56-57, 2004

    • Anthracycline and trastuzumab in breast cancer treatment.
      Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, Meerpohl HG,Thomssen C, Harbeck N, Jackisch C, Kreienberg R, Emons G, Wallwiener D, Wiese W, Schaller G, Kuhn W, Muscholl M, Pauschinger M, Langer B.
      Oncology (Williston Park) 18 (Suppl 14):59-64, 2004

    • Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
      Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Jänicke F, Thomssen C, Look MP, Foekens JA.
      Clin Breast Cancer 5(5):348-52. Review, 2004

    • Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives.
      Müller V, Pantel K.
      Breast Cancer Res 6: 258-61, 2004

    • Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
      Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ.
      J Natl Cancer Inst. 4;96(15):1141-51, 2004

    • The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas.
      Milde-Langosch K, Röder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Löning T, Bamberger AM.
      Breast Cancer Res Treat 86(2):139-52, 2004

    • The Hamburg statement: the partnership driving the European agenda on breast cancer.
      Jassem J, Buchanan M, Jänicke F, Baum M, Cataliotti L, Kyriakides S, Piccart M, Rutgers EJ, Costa A.
      Eur J Cancer;40(12):1810-1. Review, 2004

    • Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells.
      Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J,Ebel S, Jänicke F, Sauter G, Pantel K.
      Clin Cancer Res. 10(10):3422-8, 2004

    • High-Dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-Dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
      Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trumper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W.
      J Clin Oncol. 22(12):2273-83, 2004

    • HRT - quo vadis.
      Braendle W.
      Frauenarzt 45: 240-242 (2004)

    • Periklimakterium, ab wann hormonelle Therapie?
      Braendle W.
      Gynäkologische Endokrinologie 2: 283-287 (2004) Springer Verlag

    • Konsensusempfehlungen zur Hormontherapie im Klimakterium und in der Postmenopause.
      Beckmann M, Braendle W, Brucker C, Dören M, Emons G., Geisthövel F, Kiesel L, König K, Naß-Griegoleit I, Ortmann O, Rabe Th, Windler E.
      Frauenarzt 45: 620-624 (2004)

    • Empfehlungen zur hormonalen Kontrazeption. 32. Arbeitstreffen Zürcher Gesprächskreis, Mai 2004
      Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Frauenarzt 45: 1029-1032 (2004)

    • Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors.
      Müller V, Pantel K.
      Am J Cancer 2: 77-86, 2003

    • The Million Women Study, an additional observational study with the implications and limits of an observational study.
      Braendle W.
      Maturitas. 46(2):101-2, 2003

    • Detection and characterisation of occult metastatic cells in bone marrow of breast cancer patients.
      Braun S, Müller V, Pantel K.
      Micrometastasis, Kluwer Academic Press, 47-66, 2003

    • Stellungnahme des Zürcher Gesprächskreises zum Gentest [Remarks of the Zürich Discussion Panel on the gene test].
      Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kiesel L.
      Gynäkol Geburtshilfliche Rundsch. 43(1):43-52, 2003

    • Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
      Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A.
      J Clin Oncol 21(11):2101-9, 2003

    • Detection and clinical implications of early systemic tumor cell dissemination in breast cancer.
      Pantel K, Müller V, Auer M, Nusser N, Harbeck N, Braun S.
      Clin Cancer Res 9: 6326-34, 2003

    • uPA und PAI-1 haben nicht nur eine prognostische, sondern auch eine prädiktive Bedeutung und unterstützen klinische Therapieentscheidungen beim primären Mammakarzinom. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
      Harbeck N, Thomssen C.
      Zentralbl Gynäkol. 125(9):362-7, 2003

    • Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.
      Müller V, Thomssen C, Karakas C, Eustermann I, Ramirez Porras J, Coith C, Berger J, Löning T, Jänicke F, Pantel K.
      Int J Biol Markers 18: 13-20, 2003

    • Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
      Gross E, Ullrich T, Seck K, Müller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M.
      Hum Mutat 22: 498-505, 2003

    • Perspectives in oncology.
      Jänicke F.
      Onkologie26 Suppl 7:3, 2003

    • Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
      Knappe UJ, Hagel C, Lisboa BW, Wilczak W, Ludecke DK, Saeger W.
      Acta Neuropathol (Berl). 106(5):471-8, 2003

    • MR-Mammographie bei 0,5 Tesla: Menstruationszyklusabhängigkeit der Kontrastmittelanreicherung unter hormoneller Kontrazeption? [MR-imaging of the breast at 0.5 Tesla: menstrual-cycle dependency of parenchymal contrast enhancement in healthy volunteers with oral contraceptive use?].
      Lorenzen J, Welger J, Lisboa BW, Krupski G, Adam G.
      RöFo 175(4):502-6, 2003

    • [Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment].
      Schneeweiss A, Thomssen C, Harbeck N, Bastert G.
      MMW Fortschr Med 145(24):34-6, 38, 2003

    • Clinical relevance of prognostic factors in axillary node-negative breast cancer.
      Thomssen C, Jänicke F, Harbeck N.
      Onkologie 26(5):438-45. Review, 2003

    • Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
      Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Jänicke F, Pantel K.
      Int J Cancer. 107(6):903-9, 2003

    • Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
      Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR.
      Cancer Res. 63(19):6523-31, 2003

    • Molecular signature associated with bone marrow micrometastasis in human breast cancer.
      Woelfle U, Cloos J, Sauter G, Riethdorf L, Jänicke F, van Diest P, Brakenhoff R, Pantel K.
      Cancer Res. 63(18):5679-84, 2003

    • Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
      Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder M, Manders P, Edward Fiets W, Blankenstein M, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L, Klijn J, O'Higgins N, Eppenberger U,Jänicke F, Schmitt M, Foekens J.
      Thromb Haemost. 90(3):538-48, 2003

    • Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
      Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Luck HJ.
      Ann Oncol. 14(8):1227-33, 2003

    • Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
      Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Jänicke F, Pantel K.
      Clin Cancer Res. 9(7):2598-604, 2003

    • Konsensus-Empfehlungen zur Hormontherapie (HT) im Klimakterium und in der Postmenopause.
      Beckmann MW, Braendle W, Brucker C, Dören M, Emons G, Geisthövel F, Kiesel L, König K, Naß-Griegoleit I, Ortmann O, Rabe T, Windler E.
      Frauenarzt 44: 138-141 (2003)

    • Empfehlungen zur Substitution mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. 29. Arbeitstreffen des "Zürcher Gesprächskreises", November 2002.
      Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Frauenarzt 44: 390-394,2003

    • Use of oral contraceptives and risk of cancer of the uterine corpus or ovary. Two case-control studies.
      Heinemann LA, Lewis MA, Kühl-Habich D, Braendle W, Moehner S, Raff T.
      Geburtsh. und Frauenheilkunde 63: 1018-1026 (2003)

    • The Million Women Study, an additional observational study with the implications and limits of an observational study
      Braendle W.
      Maturitas 46: 101-102 (2003)

    • Empfehlungen zur hormonalen Kontrazeption. 30. Arbeitstreffen des Zürcher Gesprächskreises.
      Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
      Frauenarzt 44, 1270-1273 (2003)

    • Orale Kontrazeption und Brustkrebsrisiko.
      Braendle W.
      Gynäkologe 36: 544-545 (2003)

    • Radiotherapy after high-Dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer.
      Hoeller U, Heide J, Kröger N, Krüger W, Jänicke F, Alberti W.
      Int J Radiat Oncol Biol Phys. 53(5):1234-9 (2002)

    • Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
      Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C.
      Clin Breast Cancer 3(3):196-200. Review, 2002

    • Evidenzbasierte Empfehlungen zur Primärbehandlung von Mammakarzinomen.
      Der Konsens der AGO-Organkommission "Mamma" [Evidence-based recommendations on primary treatment of carcinomas of the breast]
      Von Minckwitz G, Brunnert K, Costa SD, Friedrichs K, Jackisch Ch, Gerber B, Harbeck N, Junkermann H, Mobus V, Nitz U, Schaller G, Scharl A, Thomssen Ch, Untch M; Conssensus of the AGO Organ Commission "Mamma".
      Zentralbl Gynäkol 124(5):293-303. Review, 2002

    • Evidenzbasierte Empfehlungen zur Behandlung von lokoregionär und fernmetastasierten Mammakarzinomen. Der Konsens der AGO-Organkommission "Mamma " [Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]
      Von Minckwitz G, Costa SD, Brunnert K, Dall P, Nitz U, Diel I, Fersis N, Friedrich M, Friedrichs K, Thomssen Ch, Gerber B, Gohring UJ, Harbeck N, Hanf V, Schaller G, Scharl A, Schmutzler R, Simon WE, Untch M; Consensus of the AGO Organ Commission "Mamma".
      Zentralbl Gynäkol 124(5):284-92, 2002

    • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
      Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.
      J Natl Cancer Inst 94(2):116-28, 2002

    • The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations.
      Schmitt M, Lienert S, Prechtel D, Sedlaczek E, Welk A, Reuning U, Magdolen V,Jänicke F, Sweep CGJ, Harbeck N.
      J Clin Ligand Assay 25: 43-52,2002

    • Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients.
      Dose J      , Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L, Habermann CR, Jänicke F.
      Nucl Med Commun 23(9):857-64, 2002

    • Positron emission tomography for the diagnosis of breast cancer.
      Rose C, Dose J, Avril N.
      Nucl Med Commun 23(7):613-8. Review, 2002

    • Endocrinology of climacteric and postmenopause.
      Braendle W      .
      Ther Umsch 59(4):199-202, 2002

    • Aktuelle Aspekte in Diagnostik und Therapie des Ovarialkarzinoms.
      Jänicke F.
      GynSpectrum 1: 3 - 6 (Springer Verlag Berlin, Heidelberg)

    • Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
      Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
      Cancer Res 62(16):4617-22, 2002

    • Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
      Friedrichs K, Hoelzel F, Jänicke F.
      Eur J Cancer 38(13):1730-8, 2002

    • Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
      Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study.
      J Clin Oncol. 20(24):4628-35, 2002

    • Perkutane Hochgeschwindigkeitsstanzbiopsie palpabler Brusttumoren: Ist die Sonographie notwendig? [Percutaneous core-needle biopsy of palpable breast tumors. Do we need ultrasound guidance?]
      Lorenzen J, Welger J, Lisboa BW, Riethdorf L, Grzyska B, Adam G.
      RöFo 174(9):1142-6, 2002

    • Expression and localization of the multidrug resistance associated protein 3 in rat small and large intestine.
      Rost D, Mahner S, Sugyama Y, Stremmel W.
      Am Journal of Physiology Gastrointest Liver Physiol 282: G720-G726, 2002

    • Vorstellung der ersten deutschen epidemiologischen Studie zu HRT und Mammakarzinom.
      Braendle W, Berger J, Flesch-Janys D, Hentschel St., Chang-Claude J, Bastert G.
      J. Menopause 2, 29-38 (2002)

    • Postpartale Depression und depressive Zustände im Klimakterium sowie unter der Hormonsubstitution.
      Braendle W, Kuhl H.
      In: Sexualhormone und Psyche (ed. H. Kuhl)Georg - Thieme Verlag, 22-28 (2002)

    • Stellungnahme des Zürcher Gesprächskreises zum Gentest.
      Birkhäuser M, Braendle W, Breckwoldt M, Keller P.J., Kiesel L. Kuhl H.
      Frauenarzt 43, 692-702 (2002)

    • Lifetime history of oral contraceptive use and development of tumours of the uterus and ovary.
      Heinemann, LAJ, Lewis, MA, Kühl-Habich D, Braendle W, Garbe E, Moehner S.
      GebFra 62, 566-573 (2002)

    • The Risk of Breast Tumours and Lifetime History of Oral Contraceptive Use.
      Heinemann LAJ, Lewis, MA, Kühl-Habich D, Braendle W, Moehner S.
      GebFra 62, 750-757 (2002)

    • Stellungnahme zu den Ergebnissen der WHI-Studie.
      Kuhl H. und Braendle W.
      GebFra 62, 917-919 (2002)

    • 28. Arbeitstreffen des Zürcher Gesprächskreises, Mai 2002 , Empfehlungen zur oralen Kontrazeption.
      Birkhäuser M, Braendle W, Breckwoldt M, Keller, PJ, Kiesel L, Kuhl H.
      Frauenarzt 43, Nr. 11, 1318-1322 (2002)

    • Disseminated breast cancer cells prior to and after high-dose therapy.
      Krüger WH, Kröger N, Togel F, Renges H, Badbaran A, Hornung R, Jung R, Gutensohn K, Gieseking F, Jänicke F, Zander AR.
      J Hematother Stem Cell Res 10(5):681-9, 2001

    • Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
      Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M.
      J Clin Oncol 19(18):3808-16, 2001

    • MAGE-A gene expression pattern in primary breast cancer.
      Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Löning T, Jänicke F, Pantel K.
      Cancer Res 61(18):6682-7, 2001

    • Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
      Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M.
      Clin Cancer Res 7(9):2757-64, 2001

    • Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
      Harbeck N, Krüger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Jänicke F.
      Onkologie 24(3):238-44. Review, 2001

    • Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
      Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.
      J Natl Cancer Inst 93(12):913-20, 2001

    • Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells.
      Krüger W, Kröger N, Togel F, Badbaran A, Renges H, Gieseking F, Gutensohn K, Jänicke F, Zander AR.
      J Hematother Stem Cell Res 10(2):303-7, 2001

    • Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
      Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M.
      J Clin Oncol 19(10):2596-606, 2001

    • Trials of new combinations of Herceptin in metastatic breast cancer.
      Thomssen C.
      Anticancer Drugs 12 Suppl 4:S19-25. Review, 2001

    • Relationship between telomerase activation and HPV 16/18 oncogene expression in squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix.
      Riethdorf S, Riethdorf L, Schulz G, Ikenberg H, Jänicke F, Löning T, Park TW.
      Int J Gynecol Pathol 20(2):177-85, 2001

    • Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells.
      Togel F, Datta C, Badbaran A, Kröger N, Renges H, Gieseking F, Jänicke F, Zander AR, Krüger W.
      J Hematother Stem Cell Res 10(1):141-5, 2001

    • Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
      Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, Nathrath W, Schwaiger M.
      J Nucl Med 42(1):9-16, 2001

    • Regulation der Ovarialfunktion.
      Braendle W.
      In: Endokrinologie und Reproduktionsmedizin I, 4. Auflage (eds. Bender, Diedrich, Künzel). Urban und Fischer. 25-45 (2001)

    • Prävalenz postmenopausaler Hormonsubstitution in Hamburg am Beispiel der Verordnungsdaten der AOK 1998 und TK 1999.
      Flesch-Janys D, Köchel A, Koch P, Berger J, Braendle W.
      GebFra 61: 995-1000 (2001)

    • Empfehlungen zur oralen Kontrazeption. 24. Arbeitstreffen "Zürcher Gesprächskreis" Mai 2000.
      Birkhäuser M, Braendle W, Breckwoldt M, Kuhl H.,Runnebaum B.
      Frauenarzt 41,1053-1058 (2000)
      J. Fertil. Reprod. 1, 36-41 (2001)

    • Ein neues orales Kontrazeptivum mit einem antimineralokortikoid und antiandrogen wirksamen Gestagen (30 µg Ethinylestradiol in Kombination mit 3 mg Drospirenon)
      Braendle W.
      GebFra 61: 101-105 (2001)

    • Estrogene, Gestagene und Brust.
      Braendle W.
      Journal für Menopause 2, 7-11 (2001)

    • Hormonsubstitution und Mammakarzinom. Stellungnahme der Kommission Hormontoxikologie der Deutschen Gesellschaft für Endokrinologie.
      Braendle W.
      Frauenarzt 42, 153 (2001)

    • Sexualhormone und Psyche. Ergebnisse des 2.Interdisziplinären Frankfurter Gesprächs zur Kontrazeption.
      Braendle W, Breckwoldt M, Kuhl H, Riecher-Rössler, Rohde A, Rüther E.
      Frauenarzt 42, 154-160 (2001)

    • Empfehlungen zur Substitution mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. 25. Arbeitstreffen des"Zürcher Gesprächskreises" November 2000.
      Birkhäuser M, Braendle W, M. Breckwoldt, P.J. Keller, H. Kuhl, B. Runnebaum.
      Frauenarzt 42, 254-258 (2001) und J. Menopause 1, 23-28 (2001)

    • Klinische Pharmakologie.
      Braendle W und Kuhl H.
      Kapitel 18: Sexualhormone und Kontrazeptiva. Rietbrock, Staib und Loew (eds.): Steinkopf Verlag Darmstadt.. 424-438, März 2001

    • Empfehlungen zur oralen Kontrazeption. 26. Arbeitstreffen des "Zürcher Gesprächskreises".
      Birkhäuser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
      Frauenarzt 42: 750-754 (2001)

    • Empfehlungen zur oralen Kontrazeption [Recommendations for oral contraception. 26th Meeting of the "Zürich Discussion Circle" March 2001]
      Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
      Gynäkol Geburtshilfliche Rundsch 41(4):246-9. Review, 2001

    • Östrogensubstitution nach Mammakarzinom? [Estrogen substitution after breast carcinoma?]
      Braendle W.
      Internist (Berl). 42(7):1039, 2001

    • Empfehlungen zur Substitution mit Östrogenen und Gestagenen im Klimakterium und in der Postmenopause [Recommendations for replacement of estrogens and progestins in climacteric and in postmenopause. 25. Arbeitstreffen des "Zurcher Gesprachskreises", November 2000]
      Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
      Gynäkol Geburtshilfliche Rundsch 41(1):12-5, 2001

    • Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen.
      Freue M, Kjaer M, Boni C, Joliver J, Jänicke F, Willemse PH, Coombes RC, Van Belle S, Perez-Carrion R, Zieschang J, Ibarra de Palacios P, Rose C.
      Breast 9(1):9-16, 2000

    • Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
      Jänicke F.
      Clin Breast Cancer 1 Suppl 1:S57-61. Review, 2000

    • Immunomagnetic tumor cell selection--implications for the detection of disseminated cancer cells.
      Krüger W, Datta C, Badbaran A, Togel F, Gutensohn K, Carrero I, Kröger N,Jänicke F, Zander AR.
      Transfusion 40(12):1489-93, 2000

    • Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
      Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J,Jänicke F, Graeff H, Schwaiger M.
      J Clin Oncol 18(8):1689-95, 2000

    • Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
      Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M.
      J Clin Oncol 18(20):3495-502, 2000

    • Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
      Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M.
      Int J Biol Markers 15(1):79-83, 2000

    • Therapy monitoring using FDG-PET in metastatic cervical cancer.
      Dose J, Hemminger GE, Bohuslavizki KH.
      Lancet Oncol 1:106, 2000

    • Das Klimakterium.
      Braendle W.
      Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2000

    • Aktuelle Fragen der Hormonsubstitution.
      Braendle W, Breckwoldt M, Göretzlehner G, Huber J, Keller P.J, Kuhl, H, Metka M, Runnebaum B, Schneider HPG.
      Frauenarzt 41, 176-184 (2000)

    • Unterscheiden sich Gestagene hinsichtlich ihres Risikopotenzials? Gemeinsame Stellungnahme der Deutschen Menopause Gesellschaft, European Menopause and Andropause Society, der Kommission Hormontoxikologie der DGE, der Deutschen Gesellschaft für Senologie, der Deutschen Krebsgesellschaft, der Schweizer Menopause-Gesellschaft und der Österreichischen Menopause-Gesellschaft.
      Braendle W, v. Holst T, Birkhäuser M, Schulz KD, Kreienberg R, Keller PJ, Huber J.
      Frauenarzt 41, 6, 714-718 (2000)

    • Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
      Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, Wieland M,Lisboa B, Cufer T, Graeff H, Selbmann K, Schmitt M, Jänicke F.
      Int J Biol Markers 15(1):73-8, 2000

    • Detection of Intramural Choriocarcinoma of the Uterus with 18F-FDG-PET. A Case Report.
      Dose J, Bohuslavizki K, Hueneke B, Lindner C, Jänicke F.
      Clin Positron Imaging 3(1):37-40, 2000

    • Do we need better prognostic factors in node-negative breast cancer?
      Thomssen C, Jänicke F.
      Eur J Cancer. 36(3):293-8, 2000

    • Sensitivity of assays designed for the detection of disseminated epithelial tumor cells is influenced by cell separation methods.
      Krüger W, Jung R, Kröger N, Gutensohn K, Fiedler W, Neumaier M, Jänicke F, Wagener C, Zander AR.
      Clin Chem 46(3):435-6, 2000

    • The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
      Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
      Cancer Res 60(3):636-43, 2000

    • Anthrazykline beim Mammakarzinom - Zusammenfassung und Perspektiven.
      Jänicke, F.
      Onkologie 23: 26-27, 2000

    • Her-2/neu als prädiktiver Faktor beim Mammakarzinom.
      Konecny G, Pegram M, Untch M, Thomssen C, Jänicke F, Hepp H, Slamon, DJ.
      Geburtsh Frauenheilk 60: 609-619, 2000

    • Decision support in breast cancer: Recent advances in prognostic and predictive techniques.
      Kates R, Harbeck N, Ulm K, Jänicke F, Graeff H, Schmitt M.
      In: Artificial intelligence techniques in breast cancer diagnosis and prognosis: Herausgeber: Jain A. et al. World Scientific Publishing Co.Pte.Ltd., Singapore. S. 55-95, 2000

    • Ovarialkarzinom - Radikale operation als Basis der Primärtherapie.
      Jänicke F.
      Frauenheilk plus (11+12): 491-493, 2000

    • Empfehlungen zur oralen Kontrazeption [Recommendations for oral contraception. 24th meeting of the "Zürich Discussion Circle"]
      Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
      Gynäkol Geburtshilfliche Rundsch 40(3-4):172-5, 2000

    • Östrogene, ein Brustkrebsrisiko? [Estrogens--a breast cancer risk?]
      Braendle W.
      Ther Umsch 57(10):646-50, 2000

    • [Postmenopausal hormone replacement under scrutiny. "Fatal therapy"?]
      Braendle W, Semler J.
      MMW Fortschr Med 142(33-34):11-2, 2000